

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-409


Pharmacology Review(s)

PHARMACOLOGY/TOXICOLOGY COVER SHEET

NDA number: 21-409
Review number: 1
Sequence number/date/type of submission: 000; 9/28/01; original submission
Information to sponsor: Yes (); No ()
Sponsor and/or agent: Merck Research Laboratory, Rahway, New Jersey
Manufacturer for drug substance: The same as above

Reviewer Name: Luqi Pei, Ph.D.
Division Name: Pulmonary and Allergy Drug Products
Division Code: HFD-570
Review Completion Date: July 19, 2002

Drug:
Trade Name: Singulair™ 4 mg Granules
Generic Name: Montelukast sodium
Code Name: L706,631
Chemical Name: Sodium 1-(((1(R)-3-(2-(7-chloro-2-quinolinyl)-(E)-ethyl)(3-(2-(1-hydroxy-1-methylethyl)propyl)thio)methyl)cyclopropane)acetate
CAS Registry Number: N/A
Molecular Formula/Weight: C₃₅H₃₅ClN₂NaO₃S; 608.2
Structure:



Manufacturer for the Drug: Merck
Relevant INDs/NDAs/DMFs: NDAs 20-829 and 20-830;
INDs 39,568, 47,726 and 58,819;
DMFs []

Drug Class: Leukotriene D₄/E₄ receptor antagonist

Indication: Asthma

Clinical formulation: Montelukast Sodium Oral Granule (4 mg/500 mg)

Ingredient	Amount (mg/packet)
Montelukast sodium (free acid equivalent)	500.0
Mannitol	
Hydroxypropyl cellulose	
Magnesium stearate	
Total packet weight	

Route of Administration:

Oral

Proposed use:

[

]

**APPEARS THIS WAY
ON ORIGINAL**

Executive Summary

I. Recommendations

A. Recommendation on Approvability

The application is approvable from the preclinical viewpoint.

B. Recommendation for Nonclinical Studies

None.

C. Recommendations on Labeling

Revise the dose ratios in the carcinogenesis, and overdose sections of the labeling (See recommended labeling section for details).

II. Summary of Nonclinical Findings

A. Brief Overview of Nonclinical Findings

Montelukast is non-genotoxic, non-carcinogenic and non-teratogenic in the preclinical toxicological evaluations. The gastrointestinal system is the primary target organ of montelukast toxicity in rats and monkeys. The secondary target organs of toxicity of the drug include the adrenals, lung, kidney, heart and lymphoid system. The No-Observed Adverse Effect Level (NOAEL) is 50 and 150 mg/kg/day for the adult rats and monkeys, respectively. The toxicity profile of montelukast in juvenile and adult monkeys is similar, but the juvenile monkey are more sensitive (NOAEL = 50 mg/kg/day).

B. Pharmacologic Activity

Montelukast is an orally active cysteinyl leukotriene antagonist. It binds to the CysLT₁ receptor with high affinity and blocks the physiologic actions of LTD₄/LTDE₄ at the receptor. The oral median effective dose of montelukast is 0.01 mg/kg in relieving allergen-induced bronchoconstriction in squirrel monkeys. The approved clinical dose of the drug for the asthma indication is 10 mg once a day in adults and 4 mg once a day in children 2 years of age and older.

C. Nonclinical Safety Issues Relevant to Clinical Use

None.

III. Administrative

/S/

A. Reviewer signature: _____ /S/

B. Supervisor signature: Concurrence - _____

/S/

Non-Concurrence - _____
(see memo attached)

TABLE OF CONTENTS - PHARMACOLOGY/TOXICOLOGY REVIEW

I. PHARMACOLOGY:..... 1

II. SAFETY PHARMACOLOGY:..... 1

III. PHARMACOKINETICS/TOXICOKINETICS:..... 1

IV. GENERAL TOXICOLOGY:..... 1

V. GENETIC TOXICOLOGY:..... 1

VI. CARCINOGENICITY:..... 1

VII. REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY:..... 1

VIII. SPECIAL TOXICOLOGY STUDIES:..... 1

IX. DETAILED CONCLUSIONS AND RECOMMENDATIONS:..... 1

X. APPENDIX/ATTACHMENTS: 5

**APPEARS THIS WAY
ON ORIGINAL**

PHARMACOLOGY/TOXICOLOGY REVIEW

Note: This document contains no review of preclinical data because no such data was submitted. The sponsor refers to relevant previous submissions for preclinical pharmacology and toxicology data of montelukast (see relevant INDs and NDAs on the cover page). Dr. Shannon Williams conducted a comprehensive review of the data and his review is attached for reference. The current review deals with the approvability and labeling review of the application only.

- I. PHARMACOLOGY:**
Not Applicable.
- II. SAFETY PHARMACOLOGY:**
Not Applicable.
- III. PHARMACOKINETICS/TOXICOKINETICS:**
Not Applicable.
- IV. GENERAL TOXICOLOGY:**
Not Applicable.
- V. GENETIC TOXICOLOGY:**
Not Applicable.
- VI. CARCINOGENICITY:**
Not Applicable.
- VII. REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY:**
Not Applicable.
- VIII. SPECIAL TOXICOLOGY STUDIES:**
Not Applicable.
- IX. DETAILED CONCLUSIONS AND RECOMMENDATIONS:**

Conclusions: The sponsor has provided sufficient evidence to support the preclinical safety of montelukast in asthmatic children — to 23 months of age. Montelukast, a leukotriene receptor antagonist, is already approved and marketed for the asthma indication in adult and pediatric patients as young as two years of age (NDAs 20-829 and 20-830). Table 1 summarizes the approved montelukast asthma applications in the Division. Notice that both dosage forms and doses differ between adult and pediatric asthmatic patients: 10-mg film-coated tablets for adults, 5-mg chewable tablets for children of six to fourteen years old, and 4-mg chewable tablets for children of two to five years old. The current application uses oral granules (a new formulation,

with the same ingredient as the chewable tablets)

Table 1. Approved Montelukast Applications

NDA No.	Dosage	Strength	Age	Indication	Approval Date
20-829	Film-coated tablets	10 mg	Adults	Asthma	20-FEB-1998
20-830	Chewable tablets	5 mg	6 – 14 yr	Asthma	20-FEB-1998
/S-008	Chewable tablets	4 mg	2 – 5 yr	Asthma	3-MAR-2000

In seeking approval of previous applications, the sponsor has extensively characterized the toxicity of montelukast in adult animals. It has also evaluated the effect of the drug in juvenile animals. The Division has reviewed all previously submitted studies (See Table 2 for these reviews). Among them, Dr. Shannon Williams' 01-DEC-1997 review of the original NDA submission is attached for reference as it provides a comprehensive summary and evaluation of all the preclinical data for montelukast.

Table 2. Relevant Previous Pharmacology and Toxicology Reviews of Montelukast

IND/NDA No.	Reviewer Name	Date of Review Completion
NDA 20-829/830	Shannon Williams, Ph.D.	December 1, 1997
NDA 20-829/830	Executive CAC report	June 11, 1997
IND 39,568	Shannon Williams, Ph.D.	June 2, 1997
IND 39,568	Shannon Williams, Ph.D.	October 24, 1996
IND 39,568	Young Sue Choi, Ph.D.	July 13, 1992

Briefly, montelukast is non-mutagenic, non-carcinogenic and non-teratogenic in the *in vitro* and *in vivo* laboratory testing. The gastrointestinal system is the primary target organ of montelukast toxicity. The secondary target organs of toxicity of the drug include the adrenals, lung, kidney, heart and lymphoid system. The No-Observed Adverse Effect Level (NOAEL) is 50 and 150 mg/kg/day for adult rats and monkeys, respectively.

The effect of montelukast on growth and development is evaluated in juvenile monkeys. In Study 94-9003 (reviewed by Dr. Shannon Williams on 24-Oct-1996 in IND 39,568), four-week-old monkeys (at the commencement of the exposure) were dosed orally with 25, 50 and 150 mg/kg/day of montelukast for 13 weeks. The gastrointestinal system was identified as a major target organ of montelukast toxicity. Treatment-related findings included epithelial vacuolation of glandular mucosa, chronic enteritis and colitis at the high dose group. The NOAEL was 50 mg/kg/day.

Available data have shown that the toxicity profile of montelukast between juvenile and adult monkeys is similar, but the juveniles are more sensitive to the drug than the adults. The higher NOAEL (150 mg/kg/day) in the adult monkeys than the juvenile monkeys (50 mg/kg/day) illustrates the point.

The current application proposes to extend the indicated pediatric population of montelukast from the age of two years down to :_____ The application does not contain any preclinical data as the Division concurred with the approach previously in a pre-NDA meeting dated April 26, 2001. The sponsor's states that "the available data in the reference NDAs are sufficient to support the preclinical safety of montelukast in pediatric asthmatic patients of _____ to two years old". This statement is reasonable. Physiological and developmental stages between 4-week-old juvenile monkeys and 6-month-old infant babies are probably comparable although the exact comparability is not known. This comparability between juvenile monkeys and babies suggests no need for additional testing in juvenile animals. Thus, the approval of the application is recommended from the preclinical viewpoint.

However, AUC ratios in sections of Carcinogenesis and Overdose of the labeling need revision. (The sponsor proposes keeping them as they are.) The reason is that the pediatric and adult patients demonstrate different plasma montelukast levels: the younger the age, the higher the plasma AUCs. Table 3 summaries the plasma drug levels and corresponding AUC ratios between the animals and different age of human populations. This review finds that the difference of 18-35% in plasma drug levels between the adult and pediatric patients is sufficient to warrant revisions of the dose ratio. The remaining sections of the preclinical labeling should remain the same.

Table 3. Human Plasma Montelukast Levels

Population (age)	6 yr - Adult	2 - < 6 yr	1 - < 2 yr	6 mo. - < 1 yr.	6 mo. - < 2 yr
AUC (ng.hr/ml)	2569	2721	3039	3471	3223
Standard Error	166	N/A	213	499	250
Ratio (pediatric/Adult)	-	1.06	1.18	1.35	1.26

Source: Vol. 1, Clinical Summary, p. 36, Table 9.

General Toxicology Issues: None.

Recommendations:

1. An approval of the application is recommended from the preclinical viewpoint.
2. Revise the dose ratios in the Carcinogenesis and Overdose Sections

**APPEARS THIS WAY
ON ORIGINAL**

Labeling with basis for findings:

This section addresses the revision of AUC ratios of the labeling for the 12-month and older patients only. The Division in an internal meeting of 24-JUN-2002 determined that the application demonstrated the safety and efficacy of montelukast in children 12 to 23 months of age, but not in the _____ New AUC ratios are calculated based on the mean plasma drug level (3.04 $\mu\text{g}\cdot\text{hr}/\text{ml}$) in children 12 – 23 months of age. Table 4 shows the newly calculated and recommended AUC ratios for the labeling. The recommended ratios are those calculated numbers rounded to the nearest 10.

Table 4. Parameters for Deriving AUC Ratios for Preclinical Labeling of Montelukast

Labeling Section	Species	Dose (mg/kg/day)	AUC ($\mu\text{g}\cdot\text{h}/\text{ml}$) ^a	AUC Ratio (animal/human)	
				Calculated	Recommended
Carcinogenesis	Mice	100	116.7 ^b	38.4	40
	Rat	200	326.9 ^c	107.5	110
Overdosage	Mice	5000	616.5 ^d	202	200
	Rat	5000	901.7 ^d	296.7	300

a. These montelukast AUC values in mice and rats were used to calculate AUC ratios for the approved labeling. (See Dr. Timothy McGovern's review dated 12-JUN-1998 and Dr. William's memorandum dated 27-FEB-1998 in NDAs 20-829 and 20-830.)

b. Average of the male and female AUCs in Study T93-034-0.

c. Average of the male (404.8 $\mu\text{g}\cdot\text{h}/\text{ml}$) and female AUCs (248.9 $\mu\text{g}\cdot\text{h}/\text{ml}$) in Study T93-054-0.

d. AUC values at 800 mg/kg in both species, for AUC values plateaus in mice and rats following a single dose of 800 mg/kg.

The new AUC ratios are recommended for both adult and pediatric populations because they provide more conservative estimates of the safety margins. Table 5 provides a comparison of the approved and the newly recommended AUC ratios. Note that the approved ratios were based on the mean plasma AUC of 2.67 $\mu\text{g}\cdot\text{hr}/\text{ml}$ in adults. (The current submission indicates that AUC in adults is 2.56 $\mu\text{g}/\text{ml}$). The recommended ratios are based on the plasma AUC of 3.04 $\mu\text{g}\cdot\text{hr}/\text{ml}$ in children of 12 – 23 months of age and are 10 – 20% smaller than the approved ones. The smaller AUC ratios provide more conservative estimates of the safety margin. Also, the difference in AUC ratios between the two populations of interest is so small that the listing of both AUC ratios is not warranted.

Table 5. Comparison of the Approved and Recommended AUC Ratios for Montelukast Labeling

Labeling Section	Approved ^a	Recommended ^d
Carcinogenicity		
Rat (200 mg/kg/day)	120	110
Mice (100 mg/kg/day)	45	40
Overdose		
Rat (5000 mg/kg)	230	200
Mice (5000 mg/kg)	340	300

a. The current approved labeling for patients aged 2 years and old.

b. Newly calculated AUC ratios based on plasma montelukast levels in children 12-23 months of age.

Additional information about the labeling review of montelukast can be found in the following documents under either NDA 20-829 or NDA 20-830:

Labeling Review by Timothy McGovern on January 27, 2000.
Addendum to Labeling Review #2 by Timothy McGovern on December 12, 1998
Labeling Review by Timothy McGovern on June 12, 1998
Memorandum by Shannon Williams, February 27, 1998

Suggested Sample Labeling (for patients 12 months of age and above):

The Carcinogenesis, Mutagenesis and Impairment of Fertility Section:

No evidence of tumorigenicity was seen in either a 2-year carcinogenicity study in Sprague-Dawley rats at oral gavage doses up to 200 mg/kg/day (estimated exposure was approximately _____ times the area under the plasma concentration versus time curve (AUC) for adults and children at the maximum recommended daily oral dose) or in a 92-week carcinogenicity study in mice at oral gavage doses up to 100 mg/kg/day (estimated exposure was approximately _____ times the AUC for adults and children at the maximum recommended daily oral dose).

...

The Overdose Section:

No mortality occurred following single oral doses of montelukast up to 5000 mg/kg in mice (estimated exposure was approximately _____ times the AUC for adults and children at the maximum recommended daily oral dose) and rats (estimated exposure was approximately _____ times the AUC for adults and children at the maximum recommended daily oral dose).

...

X. APPENDIX/ATTACHMENTS:

Addendum to review: None.

Other relevant materials (Studies not reviewed, appended consults, etc.):
Dr. Shannon Williams' review dated 01-DEC-1997.

Any compliance issues: None.

ATTACHMENT

Pharmacology and Toxicology Review of Montelukast

Shannon Williams, Ph.D.

December 1, 1997

**APPEARS THIS WAY
ON ORIGINAL**

BEST POSSIBLE COPY

DIVISION OF PULMONARY DRUG PRODUCTS
REVIEW OF PHARMACOLOGY AND TOXICOLOGY DATA
 Original Review

NDA No. 20-829 and 20,830

Submission date: 21 FEB 97

Information to be Conveyed to Sponsor: Yes (X), No ()


Reviewer: Shannon P. Williams, Ph.D. Date Review Completed: 01 DEC 97

Sponsor: Merck & Co., Inc., West Point, PA

Drug Names: *Generic:* montelukast sodium; *Commercial:* Singulair™;
Code: MK-0476, MK-476 and L-706,631

Chemical Name: [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid, monosodium salt.

Structure:



Empirical Formula: C₃₅H₃₅ClNNaO₃S (M.W. = 608.18)

Drug Product Formulation: 10 mg Tablet

Ingredient	Core Tablet (mg)	Film Coating (mg)
Montelukast sodium (free acid equivalent)	10.4 (10.0)	—
Hydroxypropyl cellulose	[]
Microcrystalline cellulose		
Lactose monohydrate		
Croscarmellose sodium		
Magnesium stearate		
Hydroxypropyl methylcellulose		
Titanium Dioxide		
Red Iron Oxide		
Yellow Iron Oxide		
Carnauba Wax Powder		
Total Tablet Weight (mg)		

Drug Product Formulation: 5 mg Chewable Tablet

Ingredient	mg/Tablet
Montelukast sodium (free acid equivalent)	5.2 (5.0)
Mannitol, USP	
Microcrystalline cellulose, NF	
Croscarmellose sodium, NF	
Hydroxypropyl cellulose, NF(EXF)	
Artificial Cherry Flavor, NF	
Magnesium stearate, NF	
Aspartame, NF	
Red Ferric Oxide, NF	
Total Tablet Weight	300.0 mg

Excipients, Degradants and Impurities: The proposed levels of all excipients, in both the adult tablet and the children's chewable tablet, occur at levels well within the ranges of those used in other currently approved drug products. Thus, there are no nonclinical issues with the proposed excipients in either the adult or pediatric formulation.

Class: cysteinyl leukotriene CysLT₁ receptor antagonist

Indication: prophylaxis and chronic treatment of asthma in adult and pediatric patients

Route: Oral

Pediatric Dose 5 mg (tablet) once daily, In a 25 kg child this is 0.25 mg/kg, 6.2 mg/m².

Adult Dose: 10 mg (tablet) once daily in adults, In a 50 kg adult this is 0.2 mg/kg, 7.4 mg/m².

Related INDs/NDAs/DMFs:

Previous Review(s), Date(s) and Reviewer(s): This NDA has not been reviewed previously. Relevant reviews of related INDs are listed below:

IND 39-568, L706,631, 13 JUL 92, Y.S. Choi, Ph.D.
 IND 39-568, L706,631, 29 OCT 92, Y.S. Choi, Ph.D.
 IND 39-568, L706,631, 25 JUL 93, Y.S. Choi, Ph.D.
 IND 39-568, L706,631, 24 OCT 96, S. P. Williams Ph.D.
 IND 39-568, L706,631, 02 JUN 97, S. P. Williams Ph.D.

APPEARS THIS WAY
ON ORIGINAL

Preclinical Studies Submitted and Reviewed in this NDA:*Note: Unless otherwise specified, studies were submitted to IND 39,568*

ACUTE TOXICITY STUDIES	[Ref. No.]	Vol./pp.
Acute Oral Toxicity Study In Mice	TT#92- 2820	1.30/H-61
PHARMACOKINETIC STUDIES		
Absorption and Disposition of MK-0476 in Mice, Rats & Monkeys*	[G-2]	29/G88
[¹⁴ C]MK-0476: Distribution in Blood and Octanol/Buffer Partition*	[G-4]	29/G199
Gastrointestinal Absorption Sites of [¹⁴ C]MK-0476 in Male Rats**	[G-5]	29/G206
Plasma Levels of MK-0476 After 14-Day Repeated Oral Administration of MK-0476 in Male Rats**	[G-6]	29/G216
Plasma Protein Binding of [¹⁴ C]-MK-0476*	[G-7]	29/G216
Tissue Distribution of Radioactivity in Rats After Oral Administration of [¹⁴ C]MK-0476*	[G-8]	29/G239
Whole Body Autoradiography in Rats**	[G-9]	29/G247
Comparison of Metabolic Profiles of MK-0476 in Human, Monkey, Rat and Mouse*	[G-12]	29/G387
Hepatic Microsomal Metabolism of MK-0476 in Mouse, Rat, Monkey and Human*	[G-15]	29/G456
LOCAL TOLERANCE		
Dermal Irritation Study in Rabbits TT #94-2649		30/H-20
Bovine Cornea BCOP Assay TT #94-4268		30/H-30
Ocular Irritation Study in Rabbits TT #94-4269		30/H-35
Dermal Irritation Study In Rabbits TT #92-2819		30/H-72
Bovine Cornea BCOP Assay TT #92-4272		30/H-98
Ocular Irritation Study In Rabbits TT #92-4269		30/H-126
SPECIAL TOXICITY		
Oral/Subcutaneous Immunogenicity Study in Guinea pigs TT #95-9805		31/Q-87

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Previously Reviewed Preclinical Studies Submitted in this NDA:

STUDY TYPE/REFERENCE NO.	Vol./pp.	Reviewer	Date of Rev.
PHARMACOLOGY STUDIES / F1- F26	28/F22-F373		
ANCILLARY PHARMACOLOGY			
Behavior and other effects in BKTO mice [F-25]	28/F-25	Choi	13 JUL 92
Cardiovascular and autonomic effects in anesthetized dogs [F-25]	28/F-25	Choi	13 JUL 92
Renal effects in conscious dogs [F-25]	28/F-25	Choi	13 JUL 92
Respiratory effects in conscious dogs [F25 and F-26]	28/F-25	Choi	13 JUL 92
Gastric acid secretion in chronic gastric fistula dogs: [F-25]	28/F26	Williams	02 JUN 97
	28/F26	Choi	13 JUL 92
PHARMACOKINETIC STUDIES			
Physiological Disposition in Rats and Monkeys/[G-1]	29/G-39	Choi	13 JUL 92
SINGLE DOSE TOXICITY			
PO Tox. Study in Mice TT #91-2787	7/A-17	Choi	13 JUL 92
IV Tox. Study in Mice TT #91-2788	7/A-17	Choi	13 JUL 92
PO Tox. Study in Rats TT #91-2789	7/A-17	Choi	13 JUL 92
IV Tox. Study in Rats TT #91-2790	7/A-17	Choi	13 JUL 92
PO TK Study in Mice. TT #92-113-0	7/A-33	Williams	02 JUN 97
PO TK Study in Rats. TT #92-031-0	7/A-98	Williams	02 JUN 97
MULTIPLE DOSE TOXICITY			
5-Wk PO Tox. Study In Monkeys TT #91-121-0	8/B-90	Choi	13 JUL 92
14-Wk PO Tox. Study In Monkeys TT #92-611-0	9/B-402	Williams	24 OCT 96
53-Wk PO Tox. Study In Monkeys TT #92-650-0	9-10/B-701	Williams	24 OCT 96
14-Wk PO Tox. In Infant Monkeys TT #94-9003	11/B-1232	Williams	24 OCT 96
5- Wk PO Tox. Study In Rats TT #91-120-0	11-12/B-1362	Choi	13 JUL 92
Range-Find (8-Day PO) Tox. in Rats TT #92-609-0	12/B-1799	Williams	02 JUN 97
14- Wk PO Tox Study In Rats TT #92-610-0	12-13/B-1820	Williams	24 OCT 96
14-Wk PO Tox./TK Study In Rats TT #92-098-0	15-16/B-3107	Williams	24 OCT 96
53-Wk PO Tox/TK Study In Rats TT #92-651-0	13-15/B-2375	Williams	24 OCT 96
16-Day PO TK Study In Rats TT #93-054-0	16/B-3585	Williams	02 JUN 97
Range-Find (8-Day PO)Tox. in Mice TT #92-070-0	16/B-3703	Williams	02 JUN 97
14-Wk PO Tox. Study in Mice TT #93-001-0	17/B-3738	Williams	02 JUN 97
5-Wk PO TK Study in Mice TT #93-034-0	17/B-3907	Williams	02 JUN 97
16-Day IV Tox. Study In Rats TT #93-144-0	17/B-4013	Choi*	27 JUL 95
16-day IV Tox Study In Monkeys TT #93-145-0	17/B-4145	Choi*	27 JUL 95
17 day IV Irritation Study In Monkeys TT #94-629-0	17/B-4371	Choi*	27 JUL 95

Choi* Studies reviewed under _____

Previously Reviewed Preclinical Studies Submitted in this NDA: (CONT...)

REPRODUCTIVE TOXICITY	Vol./pp.	Reviewer	Date of Rev.
PO Rng-find in (non-pregnant) Rabbits TT #92-716-2	19/C-48	Williams	02 JUN 97
PO Range-find in (pregnant) Rabbits TT #92-716-1	19/C-86	Williams	02 JUN 97
PO Develop. Tox. Study in Rabbits TT #92-716-0	19/C-160	Williams	02 JUN 97
MK-0476: PO TK in Pregnant Rabbits. TT#93-738-0	19/C-228	Williams	02 JUN 97
MK-0476: PO TK Study in Pregnant Rats w/ Secretion in Milk. TT#93-740-0	22/C-1282	Williams	02 JUN 97
PO Range-find Study in Rats TT #92-717-1	19/C-280	Williams	02 JUN 97
PO Develop. Tox. Study in Rats TT #92-717-0	20/C-403	Williams	02 JUN 97
PO Fertility In Female Rats TT #92-723-0	20-21/C-500	Williams	02 JUN 97
PO Fertility In Male Rats TT #93-706-0	21/C-990	Williams	02 JUN 97
PO Late Gestation & Lactation in Rats TT #93-728-0	21-22/C-1136	Williams	02 JUN 97
GENETIC /MUTAGENIC TOXICITY			
Ames Assay TT #91-8031	23/D-31	Williams	24 OCT 96
Ames Assay TT #91-8046	23/D-31	Williams	24 OCT 96
Ames Assay TT #93-8044	23/D-85	Williams	24 OCT 96
V79 M. cell Range-Find Cytotox. study TT #93-8550	23/D-141	Williams	24 OCT 96
V-79 M. Cell Mutagenesis Assay TT #93-8551	23/D-141	Williams	24 OCT 96
V-79 M. Cell Mutagenesis Assay TT #93-8563	23/D-194	Williams	24 OCT 96
Rat Hepatocyte Rng-Find Cytotoxicity TT #91-8375	23/D-240	Williams	24 OCT 96
Alkaline Elution/Rat Hepatocyte Assay TT #91-8376	23/D-240	Williams	24 OCT 96
Alkaline Elution/Rat Hepatocyte Assay TT #93-8494	23/D-289	Williams	24 OCT 96
CHO Rng-Find Cytotox. and Solubility TT #91-8881	23/D-349	Williams	24 OCT 96
In Vitro Chrom. Aberrat. in CHO Cells TT #91-8882	23/D-349	Williams	24 OCT 96
In Vitro Chrom. Aberrat. in CHO Cells TT #94-8638	24/D-420	Williams	02 JUN 97
Mouse Bone Marrow Chrom. Aberrat. TT #93-8681	24/D-487	Williams	24 OCT 96
Mouse Bone Marrow Chrom. Aberrat. TT #93-8696	23/D-487	Williams	24 OCT 96
ONCOGENIC/CARCINOGENIC POTENTIAL			
106-Week PO Carc. Study In Rats TT #93-078-0	25-26/ E-19	Williams	24 OCT 96
92-Week PO Carc. Study In Mice TT #93-110-0,-1	26-27/E-557	Williams	24 OCT 96
SPECIAL TOXICITY			
Oral Phototoxicity Study in Mice TT #91-2722	31/Q-20	Choi	13 JUL 97
PO Enzyme Induction Study in Mice [H-50] TT #91-061-0,-4	31/Q-28	Choi	13 JUL 97
Oral Enzyme Induction Study In Rats TT #91-074-0	31/Q-42	Choi	13 JUL 97
In vitro Hemolytic Assay In Rat/Human/Dog Whole Blood And Washed RBCs TT #92-4903	31/Q-60	Choi*	27 JUL 95
In Vitro Hemolytic Assay Dog Whole Blood And Washed RBCs TT #92-4909	31/Q-60	Choi*	27 JUL 95
Oral Drug Interaction Study In Mice TT #92-2651	31/Q-67	Choi	13 JUL 92


Choi* Studies reviewed under IND


Note: Portions of this review were excerpted directly from the sponsor's submission.

PHARMACOLOGY

Table 1 (below and succeeding page) presents a tabulated summary of the studies which investigated the pharmacodynamic activity of montelukast.

Table 1 Biological Activities of Montelukast





[]

Summary of Pharmacodynamic Activity:

Submitted studies on the pharmacodynamic activity of montelukast included receptor binding studies, effects on contraction of isolated tissues, effects on agonist-induced bronchoconstriction, effects on antigen-induced bronchoconstriction and other miscellaneous pharmacological studies. Receptor binding studies using guinea-pig lung, sheep lung, and human differentiated U937 cell membranes, and studies on isolated guinea-pig trachea showed that montelukast is a potent and selective competitive antagonist of the Cys LT₁ receptor. Potency and selectivity at the Cys LT₁ receptor was also demonstrated in *in vivo* studies wherein montelukast, administered by *i.v.*, aerosol or oral route inhibited leukotriene D₄-induced bronchoconstriction in guinea pigs, squirrel monkeys, and to a lesser extent in conscious sheep following aerosol administration. Montelukast was devoid of such inhibitory activity against a variety of other bronchoconstrictors including: histamine, arachidonic acid, serotonin, and acetylcholine in anesthetized guinea pigs.

A role for the Cys LT₁ receptor in antigen or ascaris-induced bronchoconstriction was demonstrated in *in vivo* models including: antigen-induced dyspnea in inbred rats, ascaris-induced bronchoconstriction in conscious squirrel monkeys and ascaris-induced early and late phase bronchoconstriction in conscious sheep, wherein montelukast was shown to be a potent and selective antagonist of the induced bronchoconstriction.

Thus, collectively the available pharmacodynamic studies suggest that Montelukast may have therapeutic value in treating human diseases such as bronchial asthma.

SAFETY PHARMACOLOGY

Previously submitted ancillary pharmacological studies included effects of montelukast on cardiovascular, renal, gastric, respiratory or CNS and behavioral parameters, where no significant activities were noted at the doses tested. The said studies have been reviewed previously (See attached Pharmacology Reviews by Dr . Choi dated 7/13/92 and by Dr. Williams dated 02

JUN 97) are more fully discussed in the Overall Summary and Evaluation Section of the Document.

PHARMACOKINETICS AND TOXICOKINETICS

Methods: The absorption, distribution, metabolism and excretion (ADME) of montelukast were studied in mice, rats, and rhesus monkeys following oral and iv dosing with Radio-labeled [¹⁴C]-montelukast ([¹⁴C]MK-0476, Batch # L-706,631-003S009), and Unlabeled MK-0476 Batch # L-706,631-001M035). The concentration of montelukast in plasma was measured by _____ Radioactivity in tissues, urine, bile and feces was determined _____

_____ The limit of detection was 0.031 µg/ml. Initially conducted pharmacokinetic studies in rats and monkeys (Ref. [G-1]) were previously reviewed (See Pharmacology Review of _____ by Dr. Choi dated 7/13/92). Although some variability between the two studies was observed, in general reported results were similar between the two studies. Thus, this review will focus on the more recent study submitted, unless indicated. Unless stated otherwise, male animals were used in the ADME studies. The animals were fasted overnight prior to oral absorption studies.

Results:

Absorption:

Oral:

Table 2 below presents a tabulated summary of the pharmacokinetics of montelukast following oral administration in rats, mice, monkeys and humans.

Table 2 Pharmacokinetics of Montelukast in Laboratory Animals and Humans After Oral Administration (Mean ± S.D.) (Sponsor's Summary Table G-2, NDA 20-829 Vol. 29 pp G-9)

Species	Dose (mg/kg)	AUC _{0-∞} (µg·min/ml)	C _{max} (µg/ml)	T _{max} (min)	F (%)	t _{1/2} ^c (min)
Rat (n=3-4)	5	100 ± 58.7	1.27 ± 1.36	22.5 ± 8.66	29.6 ± 17.3	80.2 ± 12.8 ^c
	25	580 ± 235	2.82 ± 1.61	37.5 ± 8.66	34.2 ± 13.8	176 ± 122 ^c
	50	1106 ± 325	4.35 ± 1.68	67.5 ± 26.0	32.6 ± 9.57	
	200	4795 ± 3628	15.7 ± 16.5	80.0 ± 34.6	35.3 ± 26.7	
Mouse ^a	5	180	0.940	30	45.6	
	25	705	3.72	60	35.7	
	50	2411	14.4	60	61.0	
	200	9004	34.2	120	57.0	
Monkey (n=4)	5	736 ± 191	4.54 ± 2.08	78.8 ± 48.0	36.2 ± 9.42	152 ± 29.4 ^c
	25	5360 ± 2557	21.6 ± 4.32	67.5 ± 35.7	52.8 ± 25.2	457 ± 55.9 ^c
	50	7795 ± 2751	27.3 ± 11.6	101 ± 37.5	38.4 ± 13.6	

BEST POSSIBLE COPY

	150	35456 ± 12405	60.4 ± 15.9	90.0 ± 60.0	58.2 ± 20.4	
Human ^b (n=6)	0.126	146 ± 26.5	0.385 ± 0.085	220 ± 49.0	67.3 ± 12.9	
^a Mean plasma concentrations from three animals at each sampling time were used in the estimation of pharmacokinetic parameters. ^b Clinical dose 10 mg (mean body weight = 79.3 kg) ^c [¹⁴ C]MK-0476, Batch # L-706,631-003S009; Unlabeled MK-0476 # L-706,631-001M035 ^e [Ref. G-1] Reviewed by Y.S. Choi in pharmacology review dated 7-13-92						

The Data in Table 2 above show that Montelukast was rapidly absorbed in rats and mice with increased Tmax indicative prolonged absorption seen with dose increases from 5 to 200 mg/kg in both species. Absorption was somewhat slower in monkeys and humans and in monkeys the rate of absorption appeared independent of the dose. Bioavailability (F%) although somewhat variable appeared to be independent of dose at the doses tested being around 30-35% in rats, 36-60% in mice and monkeys, with greatest bioavailability (67%) observed in humans. In rats and mice increases in doses produced roughly proportional increases in Cmax and AUC values over the doses of 5 to 200 mg/kg. In monkeys increasing doses produced roughly proportional increases in AUC values, with less than proportional increases in Cmax values over a dose range of 5 to 150 mg/kg. Comparisons between species showed that similar doses resulted in greatest exposure (Cmax and AUC) in monkeys, relative to rats and mice, where exposure was comparable. Elimination half-life values following oral dosing were not provided in the study from which the nonclinical data in Table 2 was derived [Ref G-2]. However, previously conducted pharmacokinetic studies in rats and monkeys (Reviewed by Y.S. Choi in pharmacology review dated 7-13-92) reported elimination half-life values of 80.2 ± 12.8 and 176 ± 122 min in rats and 152 ± 29.4 and 457 ± 55.9 min in monkeys following oral administration of montelukast at doses of 5 and 25 mg/kg, respectively [Ref. G-1].

Additional repeat dose pharmacokinetic testing in rats [Ref. G-6] showed similar pharmacokinetic parameters: Cmax [0.563 to 0.875 µg/ml], Tmax [40-55min], AUC [80-117 µg·min/ml], and t1/2 [87-105 min] on days 1, 8, and 14 of dosing, indicating that repeated oral administration of MK-0476 (5 mg/kg) for 2 weeks had no significant effects on its pharmacokinetic handling in rats [Ref. G-6].

Other studies conducted in rats investigated the mechanism behind the low bioavailability (33%) in rats in relation to potential intestinal metabolism and/or first pass metabolism. In vitro studies using an isolated rat intestinal loop preparation showed that introduction of a 1 mg (3-4 mg/kg) dose of [¹⁴C]-montelukast directly into the jejunum underwent negligible intestinal metabolism [Ref. G-2]. In contrast, studies which compared the steady-state drug concentrations in systemic plasma during portal or femoral vein infusion (4 mg/min estimated the first pass metabolism to be 27% [Ref. G-2]. Thus, considering the hepatic first-pass extraction, the extent of absorption for montelukast in rats was estimated to be 50%, in rats, suggesting the low bioavailability was due to the combination of incomplete absorption and hepatic first-pass elimination.

Additional studies in rats investigated the gastrointestinal (GI) absorption site(s) of montelukast [Ref. G-5] and possibility of enterohepatic circulation [Ref. G-1]. In studies on the site of absorption, injection of [¹⁴C]montelukast (5 mg/kg) into the pre-ligated duodenum, jejunum, or ileum of rats resulted in substantial plasma concentrations (0.3-0.4 mg/ml) at 15 min after dosing, whereas no plasma concentrations were observed after direct dosing in the ligated stomach. Other studies which investigated the possibility of enterohepatic circulation showed that iv. administration of montelukast (5 mg/kg) into intact and bile duct-cannulated rats resulted in comparable plasma AUC values for montelukast in both models, suggesting that enterohepatic circulation of montelukast was negligible in rats [Ref. G-1].

I.V.

Table 3 (succeeding page) presents a tabulated summary of the Pharmacokinetics of montelukast in rats mice monkeys and humans following iv administration.

**APPEARS THIS WAY
ON ORIGINAL**

Table 3 Pharmacokinetics of Montelukast in Laboratory Animals and Humans After I.V. Administration (Mean \pm S.D.) (Sponsor's Summary Table G-1 NDA 20-829 Vol. 29. pp. G-7)

Species	Dose (mg/kg)	AUC _{0-∞} (μ·min/ml)	CLp (ml/min/kg)	T _{1/2} (min)	Vd _{ss} (L/kg)
Rat (n=4)	2	136 \pm 21.9	15.0 \pm 2.27	68.9 \pm 25.1	0.467 \pm 0.143
	5	290 \pm 44.9	17.6 \pm 3.04	98.0 \pm 45.9	0.923 \pm 0.489
	10	830 \pm 136	12.3 \pm 1.91	97.4 \pm 36.8	0.681 \pm 0.340
Mouse ^a	2	158	12.7	63.6	0.906
	5	482	10.4	81.6	0.812
	10	949	10.5	81.7	0.840
Monkey (n=4)	2	812 \pm 163	2.54 \pm 0.481	135 \pm 20.5	0.199 \pm 0.055
	5	2508 \pm 653	2.09 \pm 0.487	123 \pm 38.5	0.162 \pm 0.057
	10	3634 \pm 453	2.79 \pm 0.383	123 \pm 46.5	0.185 \pm 0.050
Human ^b (n=6)	0.038	61.9 \pm 11.9	0.636 \pm 0.127	276 \pm 66.6	0.143 \pm 0.018
	0.114	197 \pm 17.0	0.585 \pm 0.075	327 \pm 10.6	0.132 \pm 0.013
	0.227	458 \pm 83.6	0.513 \pm 0.094	322 \pm 11.8	0.122 \pm 0.011

^a Mean plasma concentrations from three animals at each sampling time were used in the estimation of pharmacokinetic parameters.
^b Clinical i.v. dose (mean body weight = 79.3 kg)

Following i.v. administration, the plasma concentrations of montelukast declined in a polyphasic manner in mice, rats and monkeys. The plasma clearance CLp was relatively constant across doses in all species and averaged 15 ml/min/kg for rats, 11 ml/min/kg for mice, and 2.5 ml/min/kg for monkeys versus 0.578 ml/min/kg in humans. Likewise terminal elimination half-life values (t_{1/2}) averaged 88, 76, and 127 min in rats, mice and monkeys, respectively, whereas elimination was somewhat prolonged in humans (mean t_{1/2} = ~5 hr following single iv doses ranging from 0.38 to 0.227 mg/kg). Volumes of distribution at steady state (Vd_{ss}) in rats (range 0.467 to 0.923 L/kg) and mice (0.85 L/kg) were approximately equal to that of body water (0.6 L/kg) suggesting that the drug was distributed to the tissues. Steady state Volumes of Distribution were less in monkeys and man ranged from 0.122 to 0.199 L/kg (approximately equal to the blood + extracellular fluid volumes 0.271 l/kg) and suggest a more limited distribution to tissues. The calculated mean blood clearance (CLB) was 25 ml/min/kg for the rat, 16 ml/min/kg for the mouse and 4.1 ml/min/kg for the monkey. The pharmacokinetic parameters (CLP, t_{1/2}, and Vd_{ss}) remained relatively constant up to an i.v. dose of 10 mg/kg in the animal species studied and following iv doses ranging from 0.38 to 0.227 mg/kg in humans.

Distribution:

In Vitro Plasma Protein binding:

The extent of [¹⁴C]MK-0476 (2 to 250 μg/ml; Batch # L-706,631-004S007, specific activity = 21.22 μCi/mg and # L-706,631-004S009, specific activity = 13.58 μCi/mg) binding to plasma protein was determined in in vitro studies using blood samples from CD-1 mice Sprague Dawley rats, rhesus monkeys, and Humans. These studies showed that [¹⁴C]MK-0476 was extensively

BEST POSSIBLE COPY

bound to plasma proteins from all species, with the unbound fraction only amounting to 0.3% for mice at (10 and 50 $\mu\text{g/ml}$), 0.9% in rats and 0.4% in plasma from monkeys and human [Ref. G-7]. Further studies showed that [^{14}C] Montelukast bound to both albumin and α 1-acid glycoprotein. Binding to albumin was unsaturable, with a constant unbound fraction (0.2%), at concentrations up to 250 $\mu\text{g/ml}$, whereas binding to α 1-acid glycoprotein was saturated at a concentration of 10 $\mu\text{g/ml}$. Collectively, these studies suggest binding to albumin, may account for the majority of the extensive plasma protein binding, especially at higher drug concentrations.

In Vitro Partition Between Erythrocytes and Plasma:

In vitro studies examined the distribution of [^{14}C]MK-0476 (2 to 250 $\mu\text{g/ml}$; Batch # L-706,631-004S007, specific activity = 21.22 $\mu\text{Ci/mg}$ and # L-706,631-004S009, specific activity = 13.58 $\mu\text{Ci/mg}$) between blood cells and plasma and the partitioning of [^{14}C]MK-0476 (2-250 $\mu\text{g/ml}$) Results from these studies showed that the blood/plasma concentration ratio ($C_{\text{blood}}/C_{\text{plasma}}$) ranged from in rats, monkeys and man at all concentrations tested. In addition, the experiments revealed log P values of the concentration ratios which ranged from at the concentrations tested. These latter findings indicated that MK-0476 was fairly hydrophobic.

Tissue Distribution:

The tissue distribution of [^{14}C]Montelukast-derived radioactivity was evaluated in rats using scintillation counting following sample combustion after an i.v. administration of [^{14}C]Montelukast (5 mg/kg i.v., [Ref. G-1]). The distribution of [^{14}C]montelukast-derived radioactivity was also assessed using whole body autoradiography following single oral doses of 10 mg/kg in male rats [Ref.G-8] and after single oral doses of 5 mg/kg dose in male, nonpregnant and pregnant (Day 18 of gestation) female rats [Ref.G-9].

Table 4 (Succeeding page) presents a tabulated summary of the radioactive equivalents ($\mu\text{g/g}$ or $\mu\text{g/ml}$) observed in rat tissues at 1 to 24 hours following administration of the [^{14}C]montelukast i.v. dose.

**APPEARS THIS WAY
ON ORIGINAL**

Table 4 Radioactive Equivalents ($\mu\text{g/g}$ or $\mu\text{g/ml}$) of [^{14}C]Montelukast in the Tissues of Rats Receiving 5 mg/kg i.v. (Mean \pm SD; n=3) [Sponsors Table 17 Ref. G-1 Vol. 29 pp. G-65]

Tissue	Hours After Dose			
	1 Hour	2 Hours	4 Hours	24 Hours
Liver	7.73 \pm 0.869	4.70 \pm 0.911	2.67 \pm 0.704	0.392 \pm 0.025
Kidney	3.76 \pm 0.253	1.98 \pm 0.274	0.808 \pm 0.218	0.108 \pm 0.007
Mesenteric Lymph Nodes	3.18 \pm 2.31	1.56 \pm 0.474	1.23 \pm 0.503	0.092 \pm 0.024
Pancreas	2.41 \pm 0.840	0.847 \pm 0.205	1.26 \pm 0.817	0.100 \pm 0.013
Fat	2.01 \pm 0.221	0.900 \pm 0.189	0.380 \pm 0.020	0.076 \pm 0.011
Heart	1.71 \pm 0.267	0.877 \pm 0.092	0.396 \pm 0.071	0.161 \pm 0.012
Adrenals	1.53 \pm 0.240	0.855 \pm 0.191	0.442 \pm 0.089	0.414 \pm 0.258
Plasma	1.22 \pm 0.249	0.641 \pm 0.097	0.371 \pm 0.040	0.041 \pm 0.002
Lung	0.939 \pm 0.221	0.410 \pm 0.052	0.256 \pm 0.033	0.139 \pm 0.034
Bladder	0.813 \pm 0.147	0.416 \pm 0.097	0.240 \pm 0.092	0.101 \pm 0.022
Skin	0.703 \pm 0.119	0.314 \pm 0.038	0.190 \pm 0.089	0.072 \pm 0.028
Muscle	0.652 \pm 0.099	0.271 \pm 0.020	0.130 \pm 0.020	0.085 \pm 0.031
Spleen	0.560 \pm 0.065	0.387 \pm 0.036	0.219 \pm 0.042	0.136 \pm 0.012
Testes	0.307 \pm 0.021	0.247 \pm 0.036	0.129 \pm 0.009	0.030 \pm 0.004
Red Blood Cells	0.166 \pm 0.031	0.083 \pm 0.016	0.051 \pm 0.011	0.041 \pm 0.002
Brain	0.117 \pm 0.004	0.136 \pm 0.005	0.085 \pm 0.017	0.142 \pm 0.027
Gastrointestinal Tract (Tissue and Contents, % of Dose)				
Stomach	0.515 \pm 0.432	0.280 \pm 0.153	0.391 \pm 0.298	0.277 \pm 0.296
Small Intestine	64.8 \pm 6.74	79.5 \pm 4.23	40.0 \pm 11.7	1.05 \pm 0.238
Large Intestine	0.195 \pm 0.036	0.108 \pm 0.042	15.0 \pm 7.63	0.860 \pm 0.739
Cecum	0.175 \pm 0.040	1.18 \pm 1.75	30.6 \pm 6.45	1.90 \pm 0.512
Urine				0.468 \pm 0.122
Feces				81.1 \pm 2.40

[^{14}C]montelukast-derived radioactivity was widely distributed in rats following i.v. administration [Ref. G-1]. The majority of the radioactivity was recovered in the GI tract and feces, indicating that biliary excretion was the major route of elimination in rats. Tissues with radioactivity greater than plasma at 1 hr after dosing included: liver, kidney mesenteric lymph nodes, pancreas, fat, heart, and adrenals, with only a trace amount detected in brain. Radioactivity in all tissues declined with time, and the remaining radioactive equivalents in tissues were very low at 24 hr postdose.

Table 5 (Succeeding page) presents a tabulated summary of the radioactive equivalents ($\mu\text{g/g}$ or $\mu\text{g/ml}$) observed in rat tissues at 1 to 24 hours following oral administration of the 10 mg/kg [^{14}C]montelukast dose.

Table 5 Radioactive Equivalents ($\mu\text{g/g}$ or $\mu\text{g/ml}$) of [^{14}C]Montelukast in the Tissues of Rats Receiving 10 mg/kg p.o. (Mean \pm SD; n=3) [Sponsors Table 2 Ref. G-8 Vol. 29 pp. G-239]

Tissue	Hours After Dose		
	1 Hour	6 Hours	24 Hours
Small Intestine	85.9 \pm 39.7	27.2 \pm 6.29	1.68 \pm 0.74
Stomach	29.53 \pm 17.5	8.27 \pm 4.14	1.14 \pm 1.43
Liver	20.3 \pm 16.2	6.65 \pm 3.15	0.77 \pm 0.09
Large Intestine	15.4 \pm 1.28	24.9 \pm 15.8	1.31 \pm 0.27
Cecum	4.02 \pm 0.54	67.7 \pm 27.1	3.95 \pm 0.84
Kidney	2.56 \pm 1.20	1.95 \pm 0.45	0.21 \pm 0.07
Mesenteric Lymph Nodes	5.42 \pm 2.30	4.0 \pm 0.98	0.24 \pm 0.05
Pancreas	4.18 \pm 1.79	2.84 \pm 1.40	0.19 \pm 0.07
Fat	1.20 \pm 0.61	0.86 \pm 0.26	0.16 \pm 0.03
Heart	1.44 \pm 0.83	0.88 \pm 0.39	1.08 \pm 0.69
Adrenals	1.81 \pm 0.58	0.54 \pm 0.47	0.33 \pm 0.15
Plasma	1.23 \pm 0.75	0.49 \pm 0.13	0.07 \pm 0.02
Lung	1.62 \pm 1.25	1.51 \pm 1.84	0.39 \pm 0.27
Bladder	0.49 \pm 0.15	0.45 \pm 0.17	0.10 \pm 0.03
Skin	0.41 \pm 0.11	0.30 \pm 0.05	0.10 \pm 0.05
Muscle	0.40 \pm 0.16	0.34 \pm 0.04	0.05 \pm 0.02
Spleen	0.61 \pm 0.18	0.52 \pm 0.37	0.16 \pm 0.07
Testes	0.38 \pm 0.26	0.39 \pm 0.16	0.05 \pm 0.02
Red Blood Cells	0.19 \pm 0.11	0.15 \pm 0.02	0.06 \pm 0.04
Brain	0.12 \pm 0.06	0.84 \pm 0.70	0.68 \pm 0.54
Gastrointestinal Tract (Tissue and Contents, % of Dose)			
Stomach	33.2 \pm 17.4	4.40 \pm 2.89	1.38 \pm 2.30
Small Intestine	46.0 \pm 15.5	27.3 \pm 14.8	0.711 \pm 0.373
Large Intestine	4.63 \pm 2.25	13.0 \pm 14.1	9.94 \pm 4.22
Cecum	1.02 \pm 0.597	48.8 \pm 25.0	10.2 \pm 3.46
Urine			0.458 \pm 0.048
Feces			106 \pm 20.7
GI contents + Excreta	84.9 \pm 3.78	98.3 \pm 12.3	128 \pm 25.3
Total Recovery	111 \pm 10.6	111 \pm 13.7	130 \pm 25.2

The data in table 5 above show a pattern of distribution following oral dosing which was qualitatively similar to that seen following i.v. dosing. At 1 hr after administration of the 10 mg/kg oral dose, tissues which had levels of [^{14}C]montelukast-derived radioactivity greater than that in plasma included: in descending order small intestine, stomach, liver, large intestine,

mesenteric lymph nodes, pancreas, cecum, kidney, adrenal, lung and heart, with only trace amounts detected in the brain and red blood cells. Radioactivity declined over time with only ~1% remaining in the tissues at 24 hr after dosing. Essentially all of the radioactivity was recovered in the feces and only 0.5% recovered in the urine [Ref. G-8].

The second autoradiographic study in which a 5 mg/kg oral dose of [¹⁴C]montelukast was administered, male and nonpregnant female rats showed essentially the same pattern of distribution outlined above (i.e. highest contents observed in intestinal contents, gastric contents, mesenteric lymph nodes, bile and liver). At 96 hr after dosing only the intestinal contents of the male showed detectable levels of radioactivity.

Finally, in an autoradiographic study in pregnant rats, the distribution of [¹⁴C]-MK-0476-derived radioactivity to fetoplacental tissues was investigated following administration of a 5 mg/kg p.o. dose. At 1 hr postdose, radioactivity of stronger intensity than maternal blood was detected in the ovary and mammary glands, while intensity in the placenta, fetal membrane, uterus, fetal liver, clitoral gland, fetus and amniotic fluid was weaker than that of maternal blood. At 24 hr, radioactivity in the fetoplacental tissues was barely detectable. The pattern of distribution of radioactivity in tissues other than fetoplacental tissues was similar to that seen in non pregnant females.

Metabolism:

The metabolic profiles of MK-0476 were determined in plasma and bile samples from humans (100 mg or 50 mg, p.o.), monkey (plasma only, 50 mg/kg p.o. or 10 mg/kg i.v.), rat (20 mg/kg i.v., or 200 mg/kg p.o.) and mouse (50 or 100 mg/kg p.o.) were determined using [Ref. G-13]. Additional in vitro hepatic microsomal metabolism studies using hepatic microsomal preparations from mice, rats, monkeys and humans were conducted in order to determine the in vitro metabolism of MK-0476 as well as to identify the monooxygenase system and P-450 isoforms responsible for MK-0476 metabolism [Ref. G-15].


In all species the unchanged MK-0476 accounted for the majority of the observed plasma radioactivity. Human plasma also contained low levels of the diastereometric 21-hydroxy metabolites and 36-hydroxy metabolites. Plasma metabolites identified in mice included: the diastereomeric 21 (S)-hydroxy (M5a, L-772,146), 21(R)-hydroxy (M5b, L-772-145), and 36-hydroxy metabolites (M6a, L-775,066 and M6b, L-775,065, absolute stereochemistry unknown). Monkey plasma also contained the diastereometric 21- and 36-hydroxy metabolites and in rats all metabolites except the 36-hydroxy (M6a) metabolite were observed. Finally rat and mouse plasma showed both a sulfoxide (M1) and a phenol (M3 partial structure) metabolite, whereas only the M1 was evident in radiochromatographs from monkeys and neither metabolite was evident in human plasma radiochromatographs.

Comparison of radiochromatographic profiles of bile from human (50 mg p.o.), rat (20 mg/kg i.v. or 200 mg/kg p.o.) and mouse (50 mg/kg p.o.) revealed the following species specific differences: The major metabolite in human bile was the dicarboxylic acid (M4), whereas in rat and mouse bile, the acyl glucuronide conjugant (M1) was the major metabolite, although trace quantities of the M4 metabolite were detectable in both rat and mouse bile using

Other metabolites common to all species included a sulfoxide (M1), a phenol (M3 partial structure) and the diastereomeric 21-(M5a and M5b) and the 36-hydroxyl metabolites (M6a and M6b).

Figure 1 below presents a qualitative summary of the metabolic profiles of MK-0476 in plasma and bile from humans, monkeys, rats and mice following in vivo dosing.

Figure 1. Metabolic Pathways of Montelukast in Human, Monkey, Rat, and Mouse
(Sponsors Figure 2 Ref. G-12)



In vitro studies on the hepatic microsomal metabolism of MK-0476 showed four prominent metabolites were common to humans (adult and pediatric), mice, rats, and monkeys. These metabolites were identified as the acyl glucuronide (M1), sulfoxide, (M2), 21-hydroxylated (M5), and 36-hydroxylated (M6) metabolites. The rank order of acyl glucuronidation (M1) was: Mouse > monkey > rat > human, whereas the formation of the (M2 + M5 + M6) metabolites appeared comparable in rats, humans, and monkeys, but was somewhat less in mice (See Table 6, below). There were no significant differences in the metabolic profiles in human microsomes from adults (age = 49±8) versus pediatrics (age = 9±3). Additional kinetic studies also indicated that acyl glucuronidation was more prevalent in rodents relative to humans.

Table 6. Formation of MK-0476 metabolites by liver microsomes from mice, rats, monkeys and humans^a (Sponsor's Table 1 Ref. G-15 Vol. 29 pp. G-471)

Species	Formation of Metabolites (pmol/min/mg protein)						
	M1	M2a	M2b	M5a	M5b	M6a/b	M6a:M6b ^b
Mouse	675	13.7	21.1	1.77	6.06	2.16	13:87
Rat	486 ± 135	50.7 ± 15.5	93.4 ± 28.4	2.33 ± 0.69	8.81 ± 2.76	3.51 ± 0.88	27:73
Monkey	611 ± 91	37.4 ± 11.8	52.1 ± 13.6	3.78 ± 0.91	12.6 ± 5.01	3.47 ± 0.59	33:67
Human	251 ± 72	56.9 ± 49.2	68.8 ± 45.6	5.66 ± 5.58	13.1 ± 11.8	5.80 ± 2.93	73:27

^a Data represent mean, n=2 for mouse or mean ± SD, n=3 for rat and monkey, n=6 (M1) or 12 (M2a to M6a/b) for human

^b Ratio of diastereomers of 36-hydroxy- MK-0476 was determined by GC

1

Marker studies which identified the human P-450 isoforms responsible for MK-0476 metabolism showed that the microsomal CYP3A4 isoform catalyzed the diastereomeric sulfoxidation and 21-hydroxylation, whereas the CYP2C9 isoform selectively formed the 36-hydroxylated metabolites. Finally the rank order of percent contribution of oxidative metabolism to total in vitro metabolism of MK-0476 ($\sum V_{max}/K_m$) was: monkey (20%) = rat (20%) > human (17%) > mouse (1.3%).

Excretion:

Table 7 (below) presents a tabulated summary of the of the recovery of [¹⁴C]Montelukast-derived radioactivity following i.v. dosing in rats (5 mg/kg) and monkeys (2 mg/kg) and following oral dosing in humans (100 mg/kg).

Table 7. Recovery of [¹⁴C]Radioactivity in Urine and Feces in Rats, Monkeys and Humans (Mean ± SD) (Sponsor's Summary Table G-6 Vol. 29 pp. G31)

Species	Dose of [¹⁴ C]Montelukast	% of Dose	
		Feces	Urine
Rat (n=5)	5 mg/kg, i.v.	82.4 ± 8.89	0.71 ± 0.14
Monkey (n = 4)	2mg/kg, i.v.	88.0 ± 1.95	0.33 ± 0.03
Human (n = 6)	100 mg, p.o.	86.3 ± 3.65	0.118 ± 0.045

The data in table 7 (preceding page) show that almost essentially all of the administered radioactivity was excreted in the feces of rats monkeys and humans following oral and i.v. dosing. Biliary excretion was demonstrated to play a major role in the elimination of MK-0476. This was demonstrated by the extensive recovery of [¹⁴C]-montelukast derived radioactivity in the feces following i.v. administration in rats and monkeys [Ref. G-1]. Biliary excretion was also directly demonstrated using bile duct cannulated rats where essentially all of the radioactivity was recovered in the bile in 6 hr following administration of MK-0476 (20 mg/kg i.v.) [Ref. G-1]. Additional analysis of the metabolic profile of MK-0476 in bile from rats

indicated that unchanged drug accounted for only 4% of the dose. Thus while the unchanged parent compound accounts for the majority of circulating radioactivity, montelukast is extensively metabolized in the liver prior to its excretion in the bile and subsequent elimination in the feces in rats.

In humans recovery of radioactivity in the feces was > 86% following a single oral dose of 100 mg [¹⁴C]montelukast, with about 80% of the circulating radioactivity accounted for by the unchanged parent compound [Ref. G-13, Vol. 29 pp. G397]. However, qualitative analysis of human bile following administration of a 50 mg p.o. dose showed that MK-0476 was extensively metabolized to a major and several minor metabolites. These findings suggest that montelukast is extensively metabolized by the liver and the majority of the metabolites are excreted in the bile, with only low levels of metabolites observed in plasma. Thus, the studies in humans indicated that hepatic metabolism followed by biliary excretion plays a significant role in the elimination of montelukast and its metabolites, as was true for the other species studied.

ADME SUMMARY

Absorption following oral dosing with montelukast rapid in rats and mice at low doses (at 5 mg/kg, T_{max} = 22 and 30 min) but increased to 1.3 and 1.5 hr at top doses of 200 mg/kg. More prolonged absorption was seen in monkeys (T_{max} = 68 min to 1.7 hr over a dose range of 5 to 150 mg/kg) and humans (T_{max} = 3.7 hr at a 10 mg/day dose). Oral bioavailability of MK-0476 was greatest in humans (67%) followed by mouse and monkey (25-61%) and lowest in rats (33%).

Following i.v. dosing plasma concentrations declined in a multiexponential fashion in rats, mice, and monkeys with respective t_{1/2} values of 88, 76, and 127 min versus ~5 hr in humans. Plasma clearance is essentially constant up to 10 mg/kg i.v. in all animal species, with greatest clearance observed in rat (15 ml/min/kg) followed by mouse (11 ml/min/kg), monkey (2.5 ml/min/kg), and human (0.58 ml/min/kg). The V_{d_{ss}} of montelukast varied from 0.85 L/kg for mice (close to total body water) to 0.13 L/kg for humans (approximately equal to blood volume + extracellular fluid volume). Montelukast binds extensively (>99%) to plasma proteins (primarily albumin) and preferentially distributes to plasma component of blood (blood/plasma ratio ~ 0.65) in rats, monkeys and man. [¹⁴C]montelukast-derived radioactivity was widely distributed following i.v. and oral dosing in rats with liver, kidney, mesenteric lymph nodes, pancreas, fat, heart and adrenals showing levels greater than plasma and little radioactivity in brain and red blood cells. Autoradiographic studies in pregnant rats also showed that in addition to the aforementioned tissues, radioactivity also distributed to the ovaries and mammary glands at levels which exceeded that in blood.

Montelukast was extensively metabolized in humans, mice, rats, and monkeys with the majority of metabolites excreted in bile and feces, with only low levels of metabolites observed in plasma. Major metabolic pathways included: (a) acyl glucuronidation, (b) sulfoxidation, (c) hydroxylation of the isopropylphenyl moiety, (d) further oxidation of the 36-hydroxy metabolite to a dicarboxylic acid, and (e) hydroxylation at the 21-position. Diastereomers of the sulfoxide, 21- and 36-hydroxy and the dicarboxylic acid analogs were common to all species. In rodents, acyl glucuronidation is predominant, while in humans, oxidation at the 36-position is favored. The Cytochrome P-450 isoforms: CYP3A4 (catalyzes sulfoxidation and 21-hydroxylation) and

CYP2C9 (selectively forms the 36-hydroxylated metabolites) were exclusively responsible the formation of oxidative metabolites. Biliary excretion was shown to be the the major route of elimination of montelukast and its metabolites in rat, monkey and human, with less than 1% recovery in the urine after i.v. or oral administration.

Interspecies comparisons of PK data (i.v. and oral) and metabolic handling are contained in (Table 2 page 9 and Table 3 page 11) and Figure 1 page 15 of this review, respectively. These comparisons showed that the pharmacokinetic and metabolic handling of montelukast was qualitatively comparable in most species tested.

TOXICOLOGY

Single Dose

Exploratory Acute Oral Toxicity of L-706,631-002P in Female Mice

(TT#92-2820 Vol. 30, pp. H-61)

Methods: This study was conducted in order to attempt to find the approximate lethal dose₅₀ of L-706,631-002P, a process intermediate and dicyclohexylamine salt of MK-0476. L-706,631-002 (lot #7), was dissolved in 0.5% aqueous methylcellulose and administered to female mice via gavage at doses of 320, 800, and 2000 mg/kg (n = 3 mice/group) and at a dose 5000 mg/kg (n = 1). Mice were observed for mortality and clinical signs of drug effects for seven days after dosing.

Results: L-706,631-002P produced clinical signs of ataxia, decrease activity, bradypnea, ptosis, (2000 mg/kg only) and clonic convulsions (5000 mg/kg only) from 30 min through day 3 after dosing. Death occurred within 30 min to day 3 in the mouse at the 5000 mg/kg dose and in 1 of 3 mice at the 2000 mg/kg dose. The minimum lethal dose was 2000 mg/kg and the maximum nonlethal dose was 800 mg/kg. The LD₅₀ for L-706,631-002 was probably between 2000 and 5000 mg/kg in mice.

In conclusion, L-706,631-002P, a process intermediate and dicyclohexylamine salt of MK-0476, was well tolerated in mice at acute doses up to 800 mg/kg, p.o., but produced death preceded by signs of CNS toxicity at higher doses of 2000 and 5000 mg/kg.. The LD₅₀ for L-706,631-002P was between 2000 and 5000 mg/kg in mice.

**APPEARS THIS WAY
ON ORIGINAL**

LOCAL TOLERANCE

Exploratory Dermal Irritation Study in Rabbits TT #94-2649 (Vol. 30, pp.H-20)

Study Dates: 26 APR 94 - 15 AUG 94

Testing Lab: Merck Research Laboratories, West Point, PA

Test Articles: L-706,631-001M (lot # 24)

GLP: The study was designated as exploratory and thus was not accompanied by a signed GLP statement.

Methods: The potential for dermal irritative effects of L-706,631 was determined in rabbits (2male and 1 female) following dermal application of 500 mg (neat powder) on a 5 cm² dorsal site (covered with a gauze pad, moistened with 0.5ml of saline, and wrapped with an occlusive dressing) for 24 hours. Treatment sites were examined at 24 hr intervals and results were recorded according to the Draize scoring system (J. Pharmacol. Exp. Therap. 82:377-390)

Results: L-706,631 produced well defined erythema in all rabbits after 24 hours of treatment, becoming very slight on days 3 and 4 and resolving by day 8. Thus, the results of this study indicated that L-706,631 is a mild dermal irritant in rabbits.

Effect of L-706,631-001M024 on Bovine Corneal Opacity and Permeability (BCOP) Assay TT #94-4268 (Vol. 30, pp. H-30)

Study Dates: 26 MAY 94 to 06 OCT 94

Testing Lab: Merck Research Laboratories, West Point, PA

Test Articles: L-706,631-001M024

GLP: The study was not accompanied by a signed GLP statement.

Methods: Bovine corneas were treated with 0.75 ml of L-706,631 (20% w/v suspension with Minimal Essential Medium, MEM) and control corneas were treated with MEM alone. All corneas were then incubated in horizontal position for 4 hr at 32^o C. Corneas were then washed and tested for transparency (light transmission), an objective measure of opacity and for corneal permeability was determined by measuring the migration of fluorescein dye from the anterior to the posterior corneal compartment. (enhanced permeability represents the ability of a substance to disrupt the corneal barrier). Scores from both tests were combined to calculate an in vitro score of irritancy = opacity + 15 O.D. Previous studies with reference compounds have established agents with scores ≤ 25 as mild irritants; from 25.1 to 55 as moderate irritants and scores ≥ 55.1 as severe irritants.

Results: L-706,631 produced no corneal opacity with only a weak effect on corneal permeability (0.419 ± 0.035 versus 0.056 ± 0.002 in control) such that final irritancy scores were 6.3 for L706,631 and 1.2 for MEM controls. Thus, L-706,631 was classified as a mild irritant to the eye.

Exploratory Primary Eye Irritation Study in Rabbits TT #94-4269 (Vol. 30 pp.H-35)

Study Dates: 26 MAY 94 to 26 OCT 94

Testing Lab: Laboratories Merck Sharp & Dohme-Chibret , Centre de Recherche, Riom, FR

Test Articles: L-706,631 001M (Batch 024)

GLP: The study was not accompanied by a signed GLP statement, but was stated to be conducted in accordance with SOP.

Methods: MK-0476 (100 mg of the sodium salt powder) was placed in the conjunctival sac of the left eye of rabbits; the right eye was untreated. The eye lids were then held together for 20 sec. Ocular reactions were scored based on Draize scoring system at 15, 120 minutes, 24, 48, and 72 hours, 4 and 7 days after instillation.

Results: MK-0476 produced slight conjunctival redness and very slight to slight chemosis of bulbar conjunctiva in all rabbits at 15 to 120 min after dosing. slight corneal opacity (3 of 3 rabbits and slight iritis (2 of 3 rabbits) were also noted. The corneal opacity was increased in severity at the 24 hr time period and remained unchanged at the subsequent 48 hr time period. Most of the ocular reactions regressed in 2 of three rabbits by 72 hr after dosing but, not in the third which was killed for humane reasons due to persistent ocular signs. Maximum Draize scores ranged from 13 to 57 and occurred from 120 min to 48 hr after dosing in all three rabbits. Based on these findings the powder of MK-0476 was classified as severely irritating to the eyes of rabbits.

Dermal Irritation Study with L-706,631-002P (a process intermediate and dicyclohexylamine salt of MK-0476) in Rabbits TT #92-2819 (Vol. 30 pp.H-72)

Study Dates: 21 SEP 92 to 24 MAY 95

Testing Lab: Merck Research Laboratories, West Point, PA

Test Articles: L-706,631-002P (lot # 7)

GLP: The study was exploratory in nature and thus not accompanied by a signed GLP statement.

Methods: The potential for dermal irritative effects of L-706,631-002P, a process intermediate and dicyclohexylamine salt of MK-0476 was determined in rabbits (1 male and 2 females) following dermal application of 500 mg on a 5 cm² dorsal site (moistened with 0.5ml of saline, covered with a gauze pad then wrapped with an occlusive dressing) for 24 hours. Treatment sites were examined at 24 hr intervals and results were recorded according to the Draize scoring system (J. Pharmacol. Exp. Therap. 82:377-390)

Results: L-706,631-002P, a process intermediate and dicyclohexylamine salt of MK-0476 produced no signs of dermal irritation throughout the 8 day observation period. Thus, the results of this study indicated that L-706,631-002P had no dermal irritant effects in rabbits.

Effect of L-706,631-002P on Bovine Cornea opacity and permeability (BCOP) Assay (TT #92-4272 ;Vol. 30 pp.H-98)

Study Dates: June 95

Testing Lab: Laboratories Merck Sharp & Dohme-Chibret, Centre de Recherche, Riom, FR
Test Articles: L-706,631-002P007 a process intermediate and dicyclohexylamine salt of L-706,631.

GLP: The study was exploratory in nature and thus was not accompanied by a signed GLP statement. However, the study was stated to be conducted in accordance with SOP.

Methods: Bovine corneas were treated with 0.75 ml of L-706,631-002P007 (20% w/v suspension with Minimal Essential Medium) and control corneas were treated with MEM alone. All corneas were then incubated in horizontal position for 4 hr at 32° C. Corneas were then washed and tested for transparency (light transmission, an objective measure of opacity) and for corneal permeability (determined by measuring the migration of fluorescein dye from the anterior to the posterior corneal compartment). Enhanced permeability represents the ability of a substance to disrupt the corneal barrier). Scores from both tests were combined to calculate an in vitro score of irritancy = opacity + 15 O.D. Previous studies with reference compounds have established agents with scores ≤ 25 as mild irritants; from 25.1 to 55 as moderate irritants and scores ≥ 55.1 as severe irritants.

Results: L-706,631-002P007 produced _____ (7.75 ± 1.26 versus 0.000 ± 1.73 in controls), but had no effects on permeability such that final irritancy scores were 8.4 for L706,631 and 0.7 for _____ controls. Thus, L-706,631-002P007 was classified as a mild irritant to the eyes.

Exploratory Primary Eye Irritation Study with L-706,631-002P in Rabbits TT #92-4269
(Vol. 30 pp.H-126)

Study Dates: 02 NOV 92 to 15 JUN 95

Testing Lab: Laboratories Merck Sharp & Dohme-Chibret, Centre de Recherche, Riom, FR

Test Articles: L-706,631-002P; Batch #007

GLP: The study was exploratory in nature and thus was not accompanied by a signed GLP statement. However, the study was stated to be conducted in accordance with SOP.

Methods: L-706,631-002P, a process intermediate and dicyclohexylamine salt of MK-0476, (100 mg of the powder) was placed in the conjunctival sac of the left eye of rabbits; the right eye was untreated. The eye lids were then held together for 20 sec. Ocular reactions were scored based on Draize scoring system at 15, 120 minutes, 24, 48, and 72 hours, 6 and 7 days after instillation.

Results: L-706,631-002P produced evidence of irritation which included moderate to severe conjunctival redness and slight to severe discharge of the treated eyes, very slight to severe chemosis and slight to severe discharge were seen in all rabbits. Two rabbits showed iris congestion was noted in two rabbits and was associated with very slight edema of the cornea in one. Evidence of ocular irritant effects were first observed at the 15 min time point and were maximal (i.e. maximal Draize scores 1 to 20) between 120 and 48 hours after dosing. Evidence of irritation persisted in 2 of the three rabbits at the 72 hour time point, but were resolved in all

rabbits by Day 6 after dosing. According to the interpretation of eye irritation tests by Kay and Calandra¹, L-706,631-002P was classified as mildly irritating to the eyes of rabbits.

SUMMARY OF STUDIES ON LOCAL TOLERANCE:

Dermal and ocular studies on the local tolerance to the montelukast sodium bulk drug showed it to be mildly irritating to the skin of rabbits. In vitro Bovine Corneal Opacity and Permeability assays also indicated that montelukast had mild ocular irritant potential, whereas Draize scores indicated it to be severely irritating to the eyes of rabbits.

In additional studies reviewed herein, the local tolerance of L-706,631-002P, a process intermediate and dicyclohexylamine salt of MK-0476 was assessed. Results from these studies showed that L-706,631-002P had no dermal irritant effects in rabbits, but was classified as a mild irritant to the eyes based on the results of both the in vitro bovine corneal opacity and permeability assay and on the basis of Draize scores from in vivo studies, wherein it was administered directly to the eyes of rabbits.

Oral/Subcutaneous Immunogenicity Study in Guinea Pigs TT #95-9805 (Vol.31 pp.Q-87)

Study Dates: 16 MAR 95 to 21 JUN 95

Testing Lab: _____

Test Articles: MK-0476; L-706,631-001M (lot # 042)

GLP: The study was accompanied by a signed GLP statement.

Methods: The potential immunogenicity of MK-0476 was studied in guinea pigs.

[

]

¹ Kay J.H. and Calandra J.C.; Interpretation of Eye Irritation Tests. J. of the Society of Cosmetic Chemists. 13: 281-289, 1962

Results:

Guinea pigs immunized with MK-0476 (1 or 10 mg/animal) orally or (1 mg/animal) subcutaneously showed no systemic anaphylactic type reactions after intravenous challenge with MK-0476 (1 mg/animal). In contrast, challenge with the positive control produced severe systemic anaphylactic reactions in 4 of the 5 animals tested resulting in death in 3 of the said animals. Finally, neither MK-0476 nor conjugate induced systemic reactions in two negative control animals.

Likewise, the Four-hour failed to demonstrate a reaction in naive guinea pigs receiving intradermal injections of sera from guinea pigs administered either the MK-0476 (1 or 10 mg/animal) solution orally or the MK-0476 (1 mg/animal) emulsions subcutaneously when challenged intravenously with MK-0476 (1 mg/animal). Only 3 of the 5 sera from positive controls had of 2^6 or 2^{13} . However, 2 sera from two animals with mild and severe reactions did not show a positive reaction. from negative control animals showed no reaction.

In conclusion, under the conditions of this assay, montelukast did not induce active systemic or passive cutaneous anaphylaxis in guinea pigs.

OVERALL SUMMARY AND EVALUATION

Montelukast sodium is a potent and highly selective leukotriene D_4 (LTD_4) antagonist which acts at the structurally specific, high affinity Cys LT_1 receptor. Currently the NDA applications 20-829 and 20-830 propose to market montelukast (Singulair™, 10 mg oral tablet and 5 mg oral chewable tablet) for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 6 years of age and older.

In support of the current application the Sponsor has submitted preclinical studies including: in vitro and in vivo pharmacology, ancillary pharmacology, ADME studies in rats, mice, and monkeys including placental and milk transfer studies in rats and/or rabbits; acute single dose oral and i.v. toxicity studies in rats and mice; subacute toxicity testing in adult monkeys (5 and 14 week oral toxicity; 16 day i.v. toxicity and 17 day i.v. irritation studies), infant monkeys (14 week oral toxicity) rats (5 and 14 week oral toxicity and 16 day i.v. toxicity) and mice (5 and 14 week oral toxicity); chronic 53 week oral toxicity testing in rats and monkeys, reproductive toxicology studies (Segment I oral fertility studies in male and female rats, Segment II oral developmental toxicity studies in rats and rabbits and a Segment III oral late gestation and lactation study in rats); Genetic toxicity/mutagenic potential studies (Ames assays, V-79 mammalian cell mutagenesis assays, Alkaline Elution Rat Hepatocyte Assays, In vitro Assay for chromosomal aberrations in CHO cells, and Mouse bone marrow chromosomal aberration assays); Carcinogenicity studies (106-week oral study in rats, and 92-week oral study in mice);

Local tolerance studies (Dermal irritation in rabbits; Bovine corneal opacity and permeability assay for corneal irritation; and Ocular irritation study in rabbits) and special toxicity studies (Phototoxicity in mice, enzyme induction in mice and rats, in vitro hemolytic assay in whole blood and washed RBCs from rat, human and dog; drug interaction studies in mice; and immunogenicity studies in guinea pigs).

Pharmacodynamics: Montelukast's potency and selectivity at the Cys LT₁ receptor was demonstrated in in vitro pharmacology studies including: receptor binding studies on guinea-pig lung, sheep lung and human dU937 cell membranes, and studies on isolated guinea-pig trachea. In vivo potency and selectivity have also been demonstrated in in vivo studies where montelukast administered by the i.v., aerosol or oral route inhibited leukotriene D₄-induced bronchoconstriction in the guinea-pig (ED₅₀ = 0.001 mg/kg, i.v.; and 13 nM nebulizer concentration), squirrel monkey (ED₅₀ ~ 0.01 mg/kg p.o.), and to a lesser degree in conscious sheep when administered by aerosol. Montelukast was devoid of any activity against a variety of other bronchoconstrictors in anesthetized guinea pigs and did not inhibit the binding of 5-lipoxygenase activating protein (FLAP).

In vivo pharmacology studies also demonstrated a role for Cys LT₁ receptor activation, in the mediation of antigen-induced bronchoconstriction, wherein montelukast inhibited antigen-induced dyspnea in inbred rats (ED₅₀ = 0.032 mg/kg p.o.), ascaris-induced bronchoconstriction in conscious squirrel monkeys (ED₅₀ ~ 0.03 mg/kg p.o.), allergen induced bronchoconstriction in allergic conscious Squirrel monkeys (0.1 mg/kg p.o.) and ascaris-induced early and late phase bronchoconstriction in conscious sheep (1 mg/kg i.v. loading dose + 8 ug/kg/min i.v. infusion).

Montelukast administered to dogs in doses up to 10 mg/kg i.v. or 20 mg/kg p.o. was devoid of deleterious effects on cardiovascular, autonomic, renal, gastrointestinal, or respiratory functions and produced no significant behavioral changes in mice at oral doses up to 100 mg/kg. Thus, there were no significant ancillary pharmacological effects at the doses tested, which would raise concern for the currently proposed marketing of singulair.

Clinical studies which have demonstrated that Cys LT₁ antagonists can effectively block antigen-induced bronchoconstriction, exercise-induced bronchoconstriction, and aspirin-induced bronchoconstriction in asthmatic subjects^{2,3,4,5} portend a role for mediators such as LTD₄ and

²Rasmussen JB et al. Leukotriene D₄-receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled

LTE4 in the pathogenesis of asthma. Thus, montelukast may have therapeutic value as a LTD4 receptor antagonist in the treatment of asthma.

Pharmacokinetics: Montelukast has relatively poor oral bioavailability in rats (33%), but greater bioavailability in humans (67%) followed by mouse and monkey (25-61%). In rats, Montelukast distributed primarily to liver, kidney, mesenteric lymph nodes, pancreas, fat, heart and adrenals, with little distribution in brain and red blood cells. Montelukast crossed the placental barrier and entered the fetal circulation in rats and rabbits and significant amounts of MK-0476 transferred into the milk of lactating rats. Montelukast extensively binds (>99%) to plasma proteins (primarily albumin) in all species. Montelukast undergoes extensive oxidative metabolism in the liver, with the majority of its metabolites excreted in the bile and only low levels of metabolites observed in plasma. Its metabolic profiles were qualitatively similar across rats, mice, monkeys, and man, with major metabolites (M1-M6) formed via the following metabolic pathways: (a) acyl glucuronidation (M1), (b) sulfoxidation (M2), (c) hydroxylation of the isopropylphenyl moiety (M3), (d) further oxidation of the 36-hydroxy metabolite (M6) to a dicarboxylic acid (M4), and (e) hydroxylation at the 21-position (M5). The major metabolite in bile from rats and mice was the acyl glucuronide conjugant (M1) whereas a dicarboxylic acid (M4) was the major biliary metabolite in humans. In vitro studies using human liver microsomes showed oxidative metabolism was catalyzed mainly by cytochrome P450 enzymes and involved the P450 isoform, CYP3A4 in the sulfoxidation (M2a/b) and 21-hydroxylation (M5a/b) of MK-0476 and the CYP2C9 isoform for the 36-hydroxylation pathway (M6a/b). Biliary excretion was the major route of elimination of Montelukast and metabolites in rat, monkey and human, with less than 1% recovery in the urine after i.v. or oral administration. Elimination appeared multiexponential in rats, mice, and monkeys with respective $t_{1/2}$ values of 88, 76, and 127 min versus ~5 hr in humans.

Acute Toxicity: Acute oral and i.v. toxicity of Montelukast was evaluated in rats and mice. In rats and mice oral doses \geq 1250 mg/kg produced signs of CNS toxicity including decreased activity and ptosis in mice and decreased activity, salivation and soft stool in rats. The minimum lethal oral dose in mice and rats was > 5000 mg/kg and the oral NOEL was 625 mg/kg. The maximum non lethal i.v. dose was 78 mg/kg in rats and 156 mg/kg in mice, with 100%

antigen in patients with asthma. *J. Allergy Clin Immunol* 1992;90:193-201.

³Manning PJ et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D₄-receptor antagonist. *N Engl J Med* 1990;323:1736-1739.

⁴Christie PE et al. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. *Am Rev Respir Dis* 1991;144:957-958.

⁵Dahlén B, et al. The leukotriene antagonist MK-0679 improves baseline pulmonary function and blocks aspirin-induced airway obstruction in aspirin-sensitive asthmatics. *Am Rev Respir Dis* 1992;145 (suppl):A15.

mortality seen at the next higher doses of 156 and 312 mg/kg in rats and mice, respectively. Clinical signs of CNS toxicity (decreased activity, bradypnea, ataxia, convulsions and/or gasping) preceded death following i.v. dosing in both species. A subsequent acute toxicokinetic study in mice demonstrated a plateau for systemic exposure in mice at approximately 800-1200 mg/kg.

Subacute and Chronic Toxicity: Subacute toxicity studies were conducted in mice, rats, and monkeys, with chronic toxicity studies conducted in rats and monkeys. Primary targets organs of toxicity included the GI tract in mice, rats, and monkeys and the bone marrow in monkeys.

In mice, abdominal distention and/or cecal dilation and mortality occurred after oral dosing at levels of 800 and 1200 mg/kg for 5-weeks and at doses ≥ 200 mg/kg for 14 weeks. The NOAEL in the 14-week study in mice was 50 mg/kg (approximately 250 and 200 times, respectively, the proposed adult and pediatric doses on mg/kg basis). In single dose pharmacokinetic studies in mice oral doses of 200 mg/kg resulted in a mean AUC values of 9904 $\mu\text{g}\cdot\text{hr}/\text{ml}$, whereas AUC values at the NOAEL dose (50 mg/kg) averaged 2411 $\mu\text{g}\cdot\text{hr}/\text{ml}$.

In rats, treatment-related mortality occurred at doses of 800 mg/kg in one of two 14-week studies and at doses ≥ 200 mg/kg in a 1 year study. GI toxicity at these doses was evidenced grossly as dose-dependent dilation of the whole or part of the GI tract. However, histological correlates of ulcer of the nonglandular mucosa, moderate dilation of the cecum, atrophy of the duodenal villi, and typhlitis, were seen only in a limited number of the animals which died. Other target organs of toxicity in rats which died or were sacrificed early included: pancreas (zymogen granule depletion/cytoplasmic rarefaction), adrenals (hemorrhage/degeneration of zona granulosa), lung (edema/congestion) and lymphoid system (lymphoid atrophy of spleen, lymph nodes and thymus). Pharmacokinetic analysis in 3-month oral toxicity study in rats suggested that saturation of absorption occurred at doses 200-400 mg/kg (AUC range from 163 to 215 $\mu\text{g}\cdot\text{hr}/\text{ml}$). Animals which died in both the 3-month and 1-year toxicity studies showed comparable toxicity profiles, however death at the 200 mg/kg dose in the 1 year study versus 800 mg/kg in the 14 month study suggested that there is a duration-dependent component to the observed toxicity. The NOAEL in the 1-year rat study was 50 mg/kg. In the 3-month study in rats the 50 mg/kg dose resulted in mean exposures ($\text{AUC}_{0-24\text{h}}$) of 58.5 and 37.9 $\mu\text{g}\cdot\text{hr}/\text{ml}$ in males and females, respectively.

In adult monkeys, treatment related mortality was seen at doses of 450 mg/kg after 3 months and at 300 mg/kg after 1 year of dosing. At the 450 mg/kg dose in the 3 month study, two males which were euthanized showed GI findings of necrosis of the glandular fundic cells and depletion of mucinous cells in the stomach, and congestion, erosions and atrophy of the villi and/or mucosa of the intestines). However, GI disturbances other than soft stools and diarrhea were not seen in monkeys in the subsequent 1-year study. Toxicity to the hematopoietic system (hypoplasia/degeneration of erythropoietic tissue in the bone marrow) were seen in high dose monkeys which died or were euthanized in both the 3 month and 1-year studies. Multiple organ toxicity observed in monkeys which died included effects on: spleen (congestion, lymphoid depletion, sinusoid congestion, artery and/or fibrinoid necrosis), lymph nodes (edema and inflammatory cell infiltration of the sinusoids and/or fibrinoid arterial necrosis), thymus (lymphoid necrosis), pancreas (focal depletion of zymogen granules), adrenals (degeneration of

the zona glomerulosa and/or zona glomerulosa, and single cell necrosis, and congestion of the zona fasciculata), kidneys (hyaline cast, degeneration and single cell necrosis and epithelial cell vacuolation of the tubules), and heart (focal agonal hemorrhage and focal degeneration of the myocardium). Exposures in monkeys at doses ranging from 50 to 450 mg/kg were reduced by about 50% after 13 weeks of dosing versus Day 1 values, suggestive of possible enzyme induction or reduced absorption with repeat dosing in monkeys. The NOAEL for adult monkeys in the 1-year oral toxicity study was 150 mg/kg. The 150 mg/kg dose was shown to result in mean exposures (AUC-values) of 626.7 $\mu\text{g}\cdot\text{hr}/\text{ml}$ (after 13-weeks of repeated dosing in monkeys). Although treatment-related mortality/euthanasia occurred at a dose of 450 in the 3-month study and at a dose of 300 mg/kg in the 1-year study, determination of a possible duration dependent component to the toxicity in monkeys was not possible since the next highest dose tested in both studies (150 mg/kg, p.o.) was the NOAEL in each.

A three month toxicity study in infant monkeys (4 weeks of age) showed a toxicity profile comparable to that seen in adults (i.e. GI Toxicity including epithelial vacuolation of the glandular mucosa, chronic enteritis, and colitis in a high dose female which was euthanized and gastritis in 2 high dose males). However, infants may be more sensitive to the toxicity, since one infant monkey required euthanasia at an oral dose of 150 mg/kg, whereas in the 3-month study in adult monkeys, euthanasia was performed on two monkeys at an oral dose of 450 mg/kg. Thus, the NOAEL for infant monkeys in the 3-month oral toxicity study was 50 mg/kg versus 150 mg/kg in the 3-month study in adults.

The other most noteworthy finding observed in various studies were increases in ALT: (2-3.6 fold) in rats in a 7-day oral range finding study at doses of 800 and 1600 mg/kg and transiently (≤ 2 fold increases) in rats given doses of 100 and 200 mg/kg in a 5-week oral toxicity study. However in the latter 5-week study, observed elevations in ALT returned to control levels during the 5th week of treatment. Increases in ALT were also observed sporadically in other 3-month oral studies in rats at doses 200 mg/kg. However, correlative elevations in other liver enzymes AST and ALK were not consistently observed. In addition, elevated ALT levels were not observed in 1-year studies in rats at doses up to 400 mg/kg and no evidence of histological alterations have been correlated with these biochemical changes in any of the studies mentioned. In the 3-month and 1-year studies in monkeys, animals which died also showed increased AST and ALT levels. However, histological correlates to these findings were limited to very slight hepatocellular vacuolation observed in one high dose female which was euthanized in the 1-year study. Thus collectively, the available studies in rats and monkeys provided little evidence for toxicologically significant hepatotoxic effects in either species.

Reproduction: Effects of MK-0476 on fertility were studied in rats of both sexes. In males, MK-0476 at doses up to 800 mg/kg, p.o. ($\sim 4800 \text{ mg}/\text{m}^2$, approximately 650 times the proposed adult dose on mg/m^2 basis) produced no treatment related effects on fertility or reproductive performance. In females, oral doses of 200 mg/kg ($\sim 1200 \text{ mg}/\text{m}^2$, approximately 160 times the proposed adult dose on mg/m^2 basis) produced slight reductions in the fertility (15.8%) and fecundity (13.7 %) indexes. The next lower dose 100 mg/kg ($\sim 600 \text{ mg}/\text{m}^2$, approximately 80 times the proposed adult and pediatric doses on mg/m^2 basis) had no effects on fertility or fecundity in female rats.

Teratogenicity studies were carried out in rats and rabbits. In rats, oral (gavage) administration of MK-0476 (L-706,631) at doses up to 400 mg/kg/day (~2400 mg/m²; 300 times the proposed adult dose on mg/m² basis) and in rabbits, at doses up to 300 mg/kg/day (~3600 mg/m², approximately 490 times the proposed adult dose on mg/m² basis) during the period of organogenesis produced no evidence of embryo-fetal toxicity or teratogenicity. An overall increased fetal incidence of incomplete ossification of the pelvic bone along with reduced fetal weights and/or increases in fetal deaths was attributable to severe maternal toxicity (protracted fasting and/or blood in bottom of cage pan) in two dams at a dose of 300 mg/kg in rabbits. No evidence of maternal toxicity was observed at the next lower dose tested, 100 mg/kg/day (~1200 mg/m², approximately 160 times the proposed adult dose on mg/m² basis).

Potential developmental effects in the F1 generation were assessed in a Segment III oral late gestation and lactation study in rats. MK-0476 at doses up to 200 mg/kg (~1200 mg/m²; 160 times the proposed adult dose on mg/m² basis) had no toxicologically significant effects on pup survival, pre-weaning growth, or F1 development.

Genotoxicity: MK-0476 (L-706,631) tested negative for mutagenic/clastogenic activity in the following assay systems: microbial mutagenesis assays; mammalian cell (V-79, Chinese hamster lung cell system) HPRT mutagenesis assays, in vitro Alkaline Elution/Rat Hepatocyte assays; in vitro Chromosomal Aberration Assays in Chinese Hamster Ovary Cells and in an in vivo mouse bone marrow chromosomal aberration assay.

Tumorigenicity: In tumorigenicity bioassays MK-0476 was administered by gavage to mice for 92 weeks at doses of 25, 50, 200/100 mg/kg/day (the 200 mg/kg dose was adjusted down to 100 mg/kg during week 10 due to excessive suppression of body weight gains) and to rats at doses of 50, 100, and 200 mg/kg/day. The maximum dose tested in rats was one at which maximal absorption was demonstrated, whereas in mice it was MTD. Both studies were acceptable (see attached CAC comments). No statistically significant or dose related increases in the incidence of any tumor type was detected in either mice or rats under the conditions of the assays. Thus, MK-0476 was regarded as negative for tumorigenic activity in both the mouse and rat bioassay. In mice, the NOEL of 100 mg/kg = 300 mg/m² and is approximately 40 and 50 times the maximum proposed daily dose in adults and pediatric patients on a mg/m² basis. In rats the NOEL of 200 mg/kg = 1200 mg/m² and is approximately 160 and 190 times, respectively, the maximum proposed daily therapeutic dose in adults and pediatric patients on an mg/m² basis.

Local tolerance: Dermal and ocular studies on the local tolerance to the montelukast sodium bulk drug showed it to be mildly irritating to the skin of rabbits. In vitro Bovine Corneal Opacity and Permeability assays also indicated that montelukast had mild ocular irritant potential, whereas Draize scores indicated it to be severely irritating to the eyes of rabbits.

However, the potential for irritant effects of the bulk drug are not considered to be a risk for the patient population and the formulated therapeutic product used via the intended route of administration.

In additional studies reviewed herein, the local tolerance of L-706,631-002P, a process intermediate and dicyclohexylamine salt of MK-0476 was assessed. Results from these studies showed that L-706,631-002P had no dermal irritant effects in rabbits, but was classified as a mild irritant to the eyes based on the results of both the in vitro bovine corneal opacity and permeability assay and on the basis of Draize scores from in vivo studies wherein it was administered directly to the eyes of rabbits.

Special Toxicity: Evaluations of montelukast's potential for phototoxic effects, hemolysis in vitro, induction hepatic P-450 or peroxisomal enzyme activity in mice or rats, drug interactions in mice and immunogenic effects in guinea pigs was evaluated in a series of studies.

Tests for phototoxicity in mice showed that montelukast, at doses up to 500 mg/kg p.o., was not phototoxic for UVA, UVB or visible light spectra.

In vitro tests for hemolytic potential using rat, dog, and human blood showed that Montelukast produced hemolysis in vitro in blood from all three species. Hemolysis in human blood was observed at MK-0476 concentrations as low as 47 µg/ml in whole blood and 13 µg/ml in washed red blood cells. However, no hemolysis was reported in i.v. studies in rats or monkeys after 2 weeks of i.v. doses up to 0.72 mg/kg in rats and up to 0.36 mg/kg.

MK-0476's effects on, and/or potential to induce either P450-linked 7-ethoxy-4-trifluoromethylcoumarin O-deethylase (EFCOD) or hepatic fatty acyl CoA-oxidase activity (FACO; a non-P450 hepatic peroxisomal enzyme) were assessed in mice and rats following 4 days of repeated oral dosing. In mice, MK-0476 (400 mg/kg/day, p.o.) inhibited P450-mediated EFCOD activity (38-55%), but had no significant effects on liver weights or FACO activity. In rats oral doses of MK-0476 (400 and 800 mg/kg; p.o.) produced no effects on liver weights, EFCOD or FACO activities. These studies showed no evidence of P450 or peroxisomal enzyme induction after 4 days of repeated dosing in rats (at doses of 400 and 800 mg/kg, p.o.) or mice (at doses of 400 mg/kg p.o.). However, specific assessments of MK-0476's potential to induce either CYP3A4 [involved the sufoxidation (M2a/b) and 21-hydroxylation (M5a/b) of MK-0476 in humans] or CYP2C9 [involved in the 36-hydroxylation (M6a/b) of MK-0476 in humans] P450 isoforms, were not conducted.

Studies using immunized guinea pigs showed that intravenous challenge with MK-0476 (1 mg/animal) did not induce active systemic or passive cutaneous anaphylaxis.

Drug interaction studies in mice showed that montelukast (5000 mg/kg p.o.) produced no additive or synergistic toxicological effects when given at 1 hr post doing with prednisone (500 mg/kg; 500 times the clinical dose), theophylline (30 mg/kg; 5 times the clinical dose), or salbutamol (40 mg/kg; 500 times the clinical dose).

In conclusion, the pharmacology, pharmacokinetics and toxic potential of montelukast sodium has been evaluated extensively in multiple in vitro and in vivo studies. Treatment related gastrointestinal disturbances were observed in mice, rats and monkeys and potential hematopoietic toxicity was observed in monkeys following repeated in subacute and chronic toxicity testing. However, NOAELs observed in all repeat dose toxicity studies demonstrated wide margins of safety relative to the proposed therapeutic doses for all observed toxicity.

MK-0476 (L-706,631) showed no potential for mutagenic/clastogenic activity in a series of duplicate in vitro assays and in an in vivo assay for chromosomal aberrations in mouse bone marrow. Further, MK-0476 (L-706,631) showed no evidence of tumorigenic activity in both rat and mouse carcinogenicity bioassays.

The potential of montelukast sodium for reproductive toxicity was characterized in rats and/or rabbits, at high multiples over the proposed clinical range. Results from these studies revealed only mild effects on fertility and fecundity in female rats, but no evidence of embryofetal toxicity, teratogenicity in either species or on pup survival, preweaning growth or F1 development in rats. The NOAELs for effects on fertility and fecundity provided wide margins of safety compared to the proposed therapeutic dose.

Collectively, adequate preclinical testing and demonstration of wide safety margins for the observed toxicity, indicate no preclinical issues related to the proposed therapeutic indication. Such that from a preclinical standpoint the application is recommended for approval.

Excipients, Degradants and Impurities: The proposed levels of all excipients, in both the adult tablet and the children's chewable tablet, occur at levels well within the ranges of those used in other currently approved drug products. Thus, there are no nonclinical issues with the proposed excipients in either the adult or pediatric formulation.

The safety of the proposed limits for degradants of the both the adult and pediatric drug products _____ as well as that for impurities in the drug substance _____

_____ was qualified based on adequate exposure and margins of safety between the maximum amounts to be administered clinically and amounts administered at the NOAEL in previously conducted preclinical toxicity studies of three months or longer duration (Pharmacology review/Chemistry consult/review for safety of degradants and impurities by this reviewer dated 10/19/97).

Labeling Review:

To achieve consistency with current Divisional labeling practices, the following sections of the labeling should be revised as indicated below:

Carcinogenesis, Mutagenesis, and Impairment of Fertility

No evidence of tumorigenicity was seen in either a 2-year carcinogenicity study in Sprague Dawley rats, at oral (gavage) doses of up to 200 mg/kg/day (approximately 160 times

the maximum recommended daily oral dose in adults and 190 times the maximum recommended daily oral dose in children on a mg/m^2 basis) or in a 92 week carcinogenicity studies in mice at dose up to 100 $\text{mg}/\text{kg}/\text{day}$ (approximately 40 times the maximum recommended daily oral dose in adults and 50 times the maximum recommended daily oral dose in children on a mg/m^2 basis).

Montelukast tested negative for mutagenic/clastogenic activity

In fertility studies in female rats, montelukast produced reductions in fertility and fecundity indices at an oral dose of 200 mg/kg (approximately 160 times the maximum recommended daily oral dose in adults on a mg/m^2 basis). No effects on female fertility or fecundity were observed at 100 mg/kg (approximately 80 times the maximum recommended daily oral dose in adults on a mg/m^2 basis). Montelukast had no effects on fertility in male rats at oral doses up to 800 mg/kg (approximately 80 times the maximum recommended daily oral dose in adults on a mg/m^2 basis)

Pregnancy

Pregnancy Category B:

No teratogenicity was observed in rats at oral doses up to 400 $\text{mg}/\text{kg}/\text{day}$ (approximately 320 times the maximum recommended daily oral dose in adults on a mg/m^2 basis) and in rabbits at oral doses up to 300 $\text{mg}/\text{kg}/\text{day}$ (approximately 490 times the maximum recommended daily oral dose in adults on a mg/m^2 basis). Montelukast crosses the placenta in rats and rabbits. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

Studies in rats have shown that montelukast is excreted in milk. It is not known if SINGULAIR is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SINGULAIR is given to a nursing mother.

OVERDOSAGE

No mortality occurred following single oral doses up to 5000 mg/kg in mice (approximately 2000 times the maximum recommended daily oral dose in adults and 2400 times the maximum recommended daily oral dose in children, on a mg/m^2 basis) and rats (approximately 4100 times the maximum recommended daily oral dose in adults and 4800 times the maximum recommended daily oral dose in children, on a mg/m^2 basis). Mortality occurred at an i.v. dose of 156 mg/kg in rats (approximately 130 times the maximum recommended daily oral dose in adults and 150 times the maximum recommended daily oral dose in children, on a mg/m^2 basis) and at an i.v. dose of 312 mg/kg in mice (approximately 130 times the maximum recommended daily oral dose in adults and 150 times the maximum recommended daily oral dose in children, on a mg/m^2 basis).

No specific information is available on the treatment of overdose with SINGULAIR.

In chronic asthma studies, SINGULAIR has been administered at doses up to 200 mg/day to patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately a week without clinically important adverse experiences.

It is not known whether montelukast is dialyzable by peritoneal- or hemodialysis.

Note: Calculations of mg/m^2 doses used for comparison to clinical doses in the preclinical sections of the labeling are provided in table 8 (Succeeding page).

**APPEARS THIS WAY
ON ORIGINAL**

Table 8. Calculations for labeling revisions.
Drug: Singulair 10 mg tablets and 5 mg chewable tablets

		# daily						
	age	mg/dose	doses	mg/day	kg	mg/kg	factor	mg/m ²
Pediatric	6	5	1	5	20	0.25	25	6.25
Adult	>12	10	1	10	50	0.20	37	7.40

	route	mg/kg/d	conv. factor	mg/m ²	Dose Ratio		Rounded Dose Ratio	
					Adults	Children	Adults	Children
<u>Carcinogenicity:</u>								
mouse	p.o.	100	3	300	40.54	48.00	40	50
rat	p.o.	200	6	1200	162.16	192.00	160	190
<u>Reproduction and Fertility:</u>								
rat	po ♂ Noel	800	6	4800	648.65	N/A	650	N/A
rat	p.o. ♀	200	6	1200	162.16	N/A	160	N/A
rat	p.o. ♀ Noel	100	6	600	81.08	N/A	80	N/A
<u>Teratogenicity:</u>								
rat	p.o. ♀ Noel	400	6	2400	324.32	N/A	320	N/A
rabbit	p.o. ♀ Noel	300	12	3600	486.49	N/A	490	N/A
rabbit	p.o mat tox	300	12	3600	486.49	N/A	490	N/A
rat	p.o Seg.III	200	6	1200	162.16	N/A	160	N/A
<u>Overdosage:</u>								
mouse	p.o.	5000	3	15000	2027.03	2400.00	2000	2400
mouse	lethal i.v	312	3	936	126.49	149.76	130	150
mouse	non lethal iv	156	3	468	63.24	74.88	65	75
rat	p.o.	5000	6	30000	4054.05	4800.00	4100	4800
rat	lethal i.v	156	6	936	126.49	149.76	130	150
rat	non lethal iv	78	6	468	63.24	74.88	65	75
<u>Other:</u> (Describe studies here)								
monkey	1-year p.o.	150	12	1800	243.24	288.00	240	290
rat	1-year p.o.	50	6	300	40.54	48.00	40	50
monkey	14-wk infant	50	12	600	81.08	96.00	80	95

**APPEARS THIS WAY
ON ORIGINAL**

RECOMMENDATION

The NDAs: for SINGULAIR are approvable from a preclinical standpoint, with incorporation of the suggested revisions for the labeling sections entitled: *Carcinogenesis, Mutagenesis, and Impairment of Fertility, Pregnancy Category, Nursing Mothers, and OVERDOSAGE* as indicated above.

/S/

Shannon Williams, Ph.D.,
Pharmacologist

c.c. Original NDA 20-829 and 20-830
HFD-570/Division File
HFD-570/C.J. Sun
HFD-570/A. Trontell
HFD-570/C.S.O.
HFD-570/Shannon Williams
HFD-570/M. Himmel

Attachments: Relevant pharmacology reviews of INDs 39568 tablet, _____ chewable tablet
and _____ i.v. solution as follows:

IND 39-568, L706,631, 13 JUL 92, Y.S. Choi, Ph.D.
IND 39-568, L706,631, 24 OCT 96, S. P. Williams Ph.D.
IND 39-568, L706,631, 02 JUN 97, S. P. Williams Ph.D.
IND _____ (i.v. infusion) L706,631, 27 JUL 95, Y.S. Choi, Ph.D.
Executive CAC Report, June 11, 1997

APPEARS THIS WAY
ON ORIGINAL

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Luqi Pei
7/19/02 03:44:10 PM
PHARMACOLOGIST

Joseph Sun
7/19/02 04:01:00 PM
PHARMACOLOGIST
I concur.

**APPEARS THIS WAY
ON ORIGINAL**